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INTRODUCTION 
 
    Cancer is still an important growing problem with twelve million of new cases in the 
world per year. For the majority of tumors prognosis is unfortunately relatively poor. 
Although in the last years there were several improvements in treatment and prevention 
with a consequent decrease in deaths, the number of new diagnoses continues to 
increase. 
Alarming data from the World Health Organization (WHO) show that in 2012 cancer 
caused 8.2 million deaths.  About half in the age group between 30 and 69 years and in 
particular, data from the Associazione Italiana di Oncologia Medica (AIOM) reported 
365.500 new diagnoses in Italy in 2014. 
This disease is characterized by uncontrolled cell growth with potential property to 
spread to other tissues or sites of the body via lymph or blood (this is known as 
metastasis). In normal conditions, human cells proliferate and divide to form new cells, 
and when old or damaged, they die, and new cells take their place. In tumor conditions, 
this orderly process breaks down, indeed old or damaged cells survive when they should 
die and cells grow and divide without any control (Figure 1).  
 
 
Figure 1 
One of the most important differences between normal and cancer cells is that the latter 
are less specialized than normal ones; this is one reason that causes cancer cells dividing 
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without stopping. Furthermore, tumor-cells ignore signals to stop the proliferation or 
start apoptosis, also known as programmed cell death; these are normal “solutions” used 
by our body to remove unneeded cells.  
Cancer cells are also able to influence the microenvironment formed by the surrounding 
normal cells and blood vessels. Cancer cells facilitate angiogenic processes that lead to 
the formation of new blood vessels through which nutrients and oxygen are supplied.  
Other important property of cancer cells is the ability to evade the immune system that 
protects our body from dangerous conditions, removing abnormal or damage cells. 
It is also important to discriminate cancers from benign tumors, the first ones are 
characterized by uncontrolled growth, invasion, infiltration and sometimes metastasis, 
whereas the second ones are self-limited, non-invasive do not metastasize, have slow 
growing and can be removed by surgery (Figure 2). 
 
Figure 2 
 
Cancer affects people at all ages with the risk of cancer increases with age and with the 
presence of some risk factors, such as tobacco smoke, obesity, radiation, chemicals, 
alcohol or infectious agents.  
Cancers are caused by abnormalities present in the genetic material of the transformed 
cells.  
The genetic changes that contribute to cancer affect three main types of genes:  
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 proto-oncogenes  
 tumor suppressor genes 
 DNA repair genes  
Proto-oncogenes are normally involved in cell growth and division. When these genes 
are altered or more active than normal, they can become cancer-promoting genes or 
oncogenes. Oncogenes are typically activated in cancer cells, giving those cells new 
dangerous properties, such as protection against apoptosis, hyperactive growth and 
division, etc…. 
Tumor suppressor genes are also involved in cell growth and division. Alterations in 
these genes cause uncontrolled cell division. Tumor suppressor genes are inactivated in 
cancer cells, resulting in the loss of control over the cell cycle or DNA replication. 
DNA repair genes are involved in fixing damaged present in the DNA, such as 
mutations. When these genes are altered, the mutations can accumulate and the cells 
become cancerous. 
Unless error correction is properly carried out, the errors will survive, and might be 
passed along to daughter cells. Normally, the body use different methods to protect 
itself from cancer, for example apoptosis. 
Moreover, it is possible that mutations affect one or more checkpoints of cell cycle, G1, 
G2 and M checkpoints (Figure 3) causing uncontrolled cell cycle and uncontrolled 
mitosis.  
 
Figure 3 
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There are different types of cancer treatment. The treatment used depends on the type 
and status of the cancer and on the general state of person’s health. Typical cancer 
treatments include surgery, chemotherapy, radiotherapy, immunotherapy, hormone 
therapy, monoclonal antibody therapy, targeted therapy and stem cell transplant. To 
obtain effective strategies these treatments might be also combined. 
There are two big families of anticancer drugs: cytotoxic and cytostatic drugs.  
Cytotoxic drugs have a toxic effect on cells, indeed they are also known as “cell 
killing”. Cytostatic drugs, also called “cell stopping”, work suppressing cell growth, 
they stop the cancer cells from multiplying. The first category of medicines works by 
interfering with DNA replication, they stop cell duplication and the cells move to 
programmed cell death.  In this group are included four different classes of drugs: 
 Alkylating agents, which react covalently with DNA and distorting its shape; 
 Intercalating agents, which insert between the base pairs of DNA, thereby 
unwinding the double helix; 
 Antimetabolites, molecules with similar structure of natural nucleotides, that are 
incorporated into DNA, leading to non-functional DNA;  
 Strand-breakers, which generate reactive radicals that produce cleavage of 
polynucleotide strands. 
 
The second drug’s family includes molecules that work by interfering with mitotic 
spindle. Generally, they are natural products with complex chemical structures that 
interfere with dynamic equilibrium of the microtubules, which are essential for cell 
division and cellular integrity. They cause mitotic arrest either by blocking microtubule 
disassembly or inhibiting tubulin polymerization
1
.  
Microtubules are long, cylindrical proteins, assembled from  and  tubulin 
heterodimers (Figure 4). They are important components of the cytoskeleton and are 
involved in many cellular processes, such as cell division, intracellular transport, 
chromosome movement and mitosis
2
.  
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Figure 4 
 
Tubulin’s polymerization happens though longitudinal head-to-tail juxtaposition of 
heterodimers that form long and linear protofilaments. Thirteen aligned protofilaments 
form a microtubule within which the tubulin subunits interact through lateral and 
longitudinal bonds. When a cell begins to divide, the microtubules start assembling 
forming mitotic spindle which is really important for chromosome movement to the 
metaphase plate and for their correct segregation in sister chromatids during anaphase
3
. 
Therefore the tubulin is a really attractive target for the development of new anticancer 
compounds. 
Many synthetic or natural molecules, interfering with the dynamic assembly of tubulin, 
prevent the formation of microtubules which are key cell structures.  
Currently, the most known antitubulin agents are natural products, such as Taxanes, in 
particular Paclixatel (Taxol®) and Docetaxel (Taxotere®)
3
, Colchicine
4
, Vinca 
Alkaloids, in particular Vinblastine (VBL) and Vincristine (VCR)
5
 and Combretastatin 
A4 (CA-4)
6
 (Figure 5 ).                    
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Figure 5 
 
Taxanes are natural compounds extracted from Taxus brevifolia (Pacific yew tree) 
with a complex terpenoid structure. Most probably their anticancer activity is 
due to a lateral iso-serine side chain
7
. In 1993 Paclitaxel was FDA (Food and 
Drug Administration) approved to treat ovarian cancer’s; but in general 
Paclitaxel and its semisynthetic derivate, Docetaxel, are clinically active 
against breast, ovarian, prostate and liver tumors
3,8
. Their mechanism of action 
is different compared to Vinca alkaloid ones, in fact the Taxanes block 
7 
 
depolymerization of microtubules into tubulin whereas Vinca alkaloids inhibit 
polymerization of tubulin into microtubules
3
 (Figure 6). 
 
Figure 6 
 
However, an important advantage is represented by their poor solubility, indeed lipidic 
emulsions based on castor oil or Polisorbate 80 are necessary for their clinical use. 
Instead, Vincristine and Vinblastine, extracted from Catharanthus roseus (Vinca 
rosae), Madagascar’s plant, have hypoglycemic as well as cytotoxic activities. They are 
used for treating diabetes, high blood pressure and especially as antimitotic agents. 
They prevent microtubule assembly and block cells in phase G2/M. Vinblastine is used 
for breast cancer, Hodgkin and not-Hodgkin lymphomas’ treatment; whereas 
Vincristine is used to treat Wilm’s tumor, acute leukemia and other lymphomas9. 
Colchicine, the most commonly antitubulin agent, is a natural compound, 
isolated from Colchicum autumnale. Colchicine binds with high affinity 
tubulin, resulting in a change of its secondary structure that blocks 
microtubules’ formation.  
Finally, in 1989 Pettit et al. extracted from Combretum caffrum a highly active 
compound, Combretastatin A-4 (CA-4)
10
.   
Different studies were performed to evaluate its cytotoxic effects and in 
particular the National Cancer Institute (NCI) of Bethesda (USA) showed that 
Combretastatin A-4 has a really high activity with a GI50 of 0.32×10
-8
. 
Furthermore, it inhibits tubulin polymerization binding the colchicine binding 
site
11
. Its pro-drug, Combretastatin A-4 phosphate (CA-4P), is in phase II 
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clinical trial in UK and USA. Moreover, from magnetic resonance’ studies 
appear that CA-4P decreases bloodstream to cancer cells
12
. 
Although all these molecules have really interesting anticancer activity, they 
have also some restrictions such as neurotoxicity, development of drug-
resistance and poor bioavailability after oral administration. Therefore, 
considering these side effects, the research of new antimitotic compounds is 
still in progress.  
 
During the past years, after mitomycin discovery, a considerable interest for 
pyrrolo[1,2-a]indole system has arisen and many scientists developed several 
mitomycin analogues, also known as “mitosanes”.  Particular importance has 
been given to a new class of compounds, 9H-pyrrolo[1,2-a]indol-9-one 1
13
.  
                                     
                                                                        
Different substitutions were studied to identify the key pharmacophoric moieties of 
these compounds. The first investigations, focused on the benzene ring A, led to the 
synthesis of analogues without this ring, or in which this ring was either changed with 
some bioistoreic heterocycles or decorated with different aryl or alkyl side chains. 
Furthermore, the carbonyl group was changed with hydroxyl group or oxyimino group. 
From these modifications, a wide range of different analogues have been synthesized. 
Among these, 8H-thieno[2,3-b]pyrrolizinones 2, more recently named “tripentones”, 
represent an interesting class of anti-cancer agents, due to their cytotoxicity against 
tumor cells in the submicro-nanomolar range
14-16
. 
1 
 
 
 Mitomycin  
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Different tripentones analogues have been synthesized to confirm the importance of 
thienopyrrolizinone core. The 3-aryl-8H-thieno[2,3-b]pyrrolizin-9-ones, tested on 60 
tumor cell lines (NCI), have shown high cytoxicity
16
. Many derivatives were selective 
against the leukemia subpanel and the most promising analogs were 2a, 2b and 2c
13
. 
 
 
 
In particular, compound 2b resulted the most active and characterized by high 
cytotoxicity (IC50 = 0.015 M). Further studies on this derivative showed that it acts on 
tubulin polymerization (IC50 = 2.9 M) causing cell cycle arrest in the G2/M phase. 
This effect was comparable to famous tubulin inhibitors such as Vinca alkaloids or 
Docetaxel. 
 
It was also able to induce apoptosis through the MAP kinase pathway. 
Derivative 2b compared with a reference compound, Combretastatin A-4, shows an 
increase in a modest manner of the percentage of cells in the first phase of apoptosis. A 
dose-dependent activation of caspases 3 and 7 confirms the involvement of tripentone 
2b in programmed cell death’s process. Moreover, this compound was also evaluated 
against a panel of several kinases and showed interesting inhibitory activity against 
Cdk1/cyclin B (IC50 = 5.5 M) and GSK-3 (IC50 = 1.5 M)
13
. Strong inhibitor activity 
was showed against FLT3-ITD (Internal Tandem Duplication) (Kd = 1.4 M). This 
derivative seems to be a promising hit compound for hematologic cancers’ treatment 
due to its high selectivity towards this FLT3 tyrosine kinase’s mutation that was the 
most commune genetic abnormality in Acute Myeloid Leukemias (AMLs)
17
.  
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Unfortunately in vivo studies showed an insufficient bioavailability due to a lack of 
solubility in physiological conditions
13
. 
New tripentone systems were synthesized, in which the thiophene ring was replaced by 
a bioisosteric analogues such as furan 3, pyrrole 4 and benzene 5
16
, or by isomers as 
thiophenes 6 and 7. Moreover, several heterocyclic tripentones such as pyrazole 8, 
pyrazine 9, pyridothieno- 10 and indole 11 pyrrolizinones were synthesized
13,16,18
. 
 
 
 
Unfortunately all new series of compounds appeared less active than the lead 
compound. Indeed some pyrrolo- and furo-pyrrolizinone derivatives exhibited a modest 
activity at micromolar concentrations (IC50 = 8.9-64 μM) with a weak inhibitory activity 
(micromolar range) against several cyclic-dependent kinases (CDKs1-5, GSK-3)19-20. 
Several indole-pyrrolizinones showed modest activity against leukemia sub-pannel, 
renal cancer sub-pannel and non–small cell lung cancer sub-pannel at micromolar 
concentrations
18
. 
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At the light of these data with the aim to improve pharmacokinetics properties of lead 
compounds, another series of pyrroloquinoxaline of type 12, characterized by hydrazine 
side chains, have been synthesized. Pyrroloquinoxaline derivatives have shown an 
interesting cytotoxicity (IC50 = 0.3-4 M) in a panel of four human cell lines, one breast 
cancer cells and three colon cancer cells. 
The presence of carbohydrazide linker and a planar arrangement seem necessary for 
their activity
21
. 
 
 
Following series of N’-heteroacyl-9H-pyrrolo[1,2-a]indol-9-hydrazones 13 were 
planned by Grande et al.
22
, in which the central pyrazine ring was contracted from six to 
five terms by removal of N-5 atom, while the presence of heteroaryl carbohydrazide 
side chains was maintained. This new series of compounds was planned with the aim to 
improve pharmacokinetic properties and obviously the efficacy.   
 
 
 
All new compounds were tested in a panel of six human cancer cell lines belong to 
breast cancer, colon cancer and cisplatin-resistant ovarian cancer. Although new 
derivatives weren’t most active then lead compounds, the pharmacokinetics profile 
resulted of course improved
22
. 
Ar = 
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AIM OF THE WORK 
 
From several years the research group where I carried out my PhD thesis has been 
interested in the synthesis and biological evaluation of polycondensed nitrogen 
heterocycles, containing pyridine or aza-indole moieties, endowed with antineoplastic 
activity. 
Considering the significant biological properties of tripentones, our aim was the 
synthesis of new analogues in which the thiophene ring was replaced by a pyridine ring 
14-16 or by aza-indole ring 17-18 in order to assess how these structural modifications 
can influence the antitumor activity. Moreover, we decorated the new tripentones with 
heteroaryl carbohydrazide chains, offering a possibility of forming conjugate salts to 
improve water solubility, in order to improve their pharmacokinetic properties.  
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MOLECULAR DOCKING STUDIES 
 
Considering the interesting biological activities of our lead compounds and in particular 
against tubulin, with the aim of studying the potential interaction of our new compounds 
14-18, molecular modeling studies were performed on this target. 
Tubulin-interacting agents (MDAs, microtubule-targeted agents), are compounds able 
to interfere with tubulin normal functions. They can act inhibiting its polymerization 
causing microtubule mass decrease, or they can increase the length of microtubules and 
consequently their stability. On these bases, they are divided in two mains groups 
depending on their mode of action (Figure 7): 
 Microtubule-destabilizing agents 
 Microtubule-stabilizing agents 
 
Figure 7 
To Microtubule-destabilizing agents belong Vinca alkaloids and colchicine which 
binding sites are very close each other but they are not the same. Vinca alkaloids bind to 
β tubulin close to GTP binding site and they have two distinct sites on microtubules: 
binding site with high affinity at the microtubule end and one with low affinity along 
the sides of microtubule surface
23-24
. Colchicine binds to tubulin at the interface of α,β 
14 
 
subunits to give a soluble intermediate complex that undergoes to polymerization. The 
presence of colchicine causes obstruction of the lateral contacts between protofilaments 
inhibiting cell mitosis
25
.  
To Microtubule-stabilizing agents belong Taxanes, Laulilamide or Peroluside, and 
Epothilones (Figure 8). 
                                         
                Laulimalide                                                                  Peroluside 
 
                                                     Epothilone A: R= H 
                                                     Epothilone B: R= Me 
Figure 8 
Taxanes, such as Paclitaxel, bind to a pocket of the interior lumen of β tubulin facing 
the central cavity in the microtubule
26-29
. Paclitaxel at very beginning exerts its function 
binding a pocket located in the outer microtubule surface. It cause a β tubulin 
rearrangement followed by its penetration in the microtubule. This action finally results 
in stabilizing the GDP-bound- β -tubulin protofilaments giving a more stable structure30. 
Paclitaxel shows different behaviors depending on its concentration. At low 
concentrations, it acts as Vinca alkaloids or colchicines, decreasing microtubule 
dynamicity, causing the arrest of the cell cicle, while at higher concentrations promotes 
tubulin polymerization. 
15 
 
Epothilones are macrolide antibiotics that stabilize microtubule in a way similar to that 
of taxanes
31
. They induce mitotic arrest in the G2/M phase of the cell cycle, causing 
apoptosis. Epothilones compete with taxanes for binding with tubulin and are able to 
displace them from microtubules. Although they are able to promote these events, 
electron crystallography studies showed that they interact with a binding site close to 
that of taxanes, both located in the β subunit of tubulin, with an independent molecular 
interactions
32
.  
Laulilamide is a 20-membered ring isolated from a marine sponge. It binds a specific 
site of the β subunit and show antimitotic activity similar to that of taxanes33-36.  
α, β Subunits of tubulin share about 50% sequence homology. Each monomer is 
constituted by a C-terminal domain (red), an N-terminal domain (blue) and an 
intermediate domain (orange) (Figure 9). 
The C-terminal domain is formed by 2 antiparallel α helices (H11-H12) with an internal 
surface formed by different loops.  
 
 
Figure 9 
 
The N terminal domain is composed by 6 β sheets (S1-S6), 2 α helices (H1-H6), a 
nucleotide binding site (Loop T1-T6), and a binding site constituted by 3 α-helices (H8-
H10) and 3 β-sheets (S7-S10). The intermediate domain provides loop T7 that activates 
16 
 
nucleotide hydrolysis in the protofilament when inserted into the active site of the next 
subunit
37
. 
MDAs can be classified also depending on their binding sites that have different 
locations as showed in figure 10.  
 
Figure 10 
In particular, to date, four different binding sites are known: 
 Colchicine binding site 
 Vinca alkaloids binding site (vinblastine) 
 Taxanes binding site (epothilone) 
 Laulilamide binding site (peroluside). 
The colchicine binding site was identified by Ravelli et al. in 2004 by the determination 
of a 3.5 Å X-ray structure of α, β-tubulin with pdb code 1SA0, complexed with N-
deacetyl-N-(2-mercaptoacetyl) colchicine (DAMA-colchicine)
38
. This structure also 
shows the the stathmin-like domain RB3. Experimental data showed that colchicine 
binds to β-tubulin at its interface with α-tubulin (Figure 11), resulting in inhibition of 
tubulin polymerization. 
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Figure 11 Structure 1SAO with DAMA-colchicine (green) 
 
In particular, the trimethoxyphenyl groups of both DAMA-colchicine in the β-tubulin 
structure are in the vicinity of the amino acid residue Cysβ241. The width of the 
colchicine binding site is approximately 4–5 Å, and the volume of this site is confined 
in β-tubulin by helix 7 (H7) containing Cysβ241, loop 7 (T7) and helix 8 (H8). 
Recently another structure was published by Porta et al. with a better resolution (2.3 Å) 
and with pdb code 4O2B
39
 in which tubuline is co-crystallized with colchicine.  
The Vinca alkaloids binding site is described in the X-ray structure, avalaible with pdb 
code of 1Z2B
40
, published by Giganti et al.. In this structure vinblastine is the co-
crystallized ligand, located in the β subunit (Figure 12). 
18 
 
 
Figure 12 Structure 1Z2B with vinblastine (light blue) 
 
The vinblastine site comprises sites located in the inner lumen of microtubules and 
involved in longitudinal protofilament contacts. This site is constituted by the area 
surrounded by loop T7, helix H10 and strand S9 in the α subunit and by the carboxy-
terminal turn of helix H6 and loop T5 and H6-H7 in the β subunit. 
There are not available structures with taxanes or paclitaxel as ligands. Recently it was 
published the tubulin structure with Epothilone A (pdb 4O4I)
41
. The same structure is 
also co-crystallized with Laulilamide (Figure 14). 
The taxanes binding site is located on the luminal side of the microtubule and is formed 
by helix H7, β strand S7, the M-loop, loops H6-H7 and S9-S10. 
Laulilamide binding site is located in a pocket on β tubulin that is formed by 
hydrophobic and polar residues of helices H9 and H10 and the loops H9-H9’ and H10-
S9.  
19 
 
 
Figure 13 Structure 4O4I with Epothilone A (orange) and Laulilamide (light blue) 
Considering that any information about our lead compounds’ binding site are available, 
different X-ray crystallographic structures were selected for our computational studies. 
In particular, three structures representative of the four known tubulin binding sites, 
were selected: 
1. 1Z2B for Vinca alkaloids binding site; 
2. 4O4I for both Taxanes and Laulilamide binding sites;  
3. 4O2B for Colchicine binding site 
For Colchicine binding site the most used structure is that with pdb code 1SA0
38
 
published by Ravelli et al., but the X-ray structure 4O2B
39
 was selected, considering the 
better results obtained in the re-docking and the better resolution.  
All X-ray structures were downloaded from the Protein Data Bank 
(http://www.rcsb.org) and prepared using Schrodinger’s Protein Preparation Wizard of 
Prime module
42
 for protein structure refinement, through which the stathmin-like 
domain and the subunits, no directly involved in the binding site, were removed. 
Ligands preparation and docking studies were performed using Extra Precision mode 
(XP) of Glide module of Schrodinger. In order to evaluate the reliability of Glide 
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protocol, the re-docking of the co-crystallized ligand was performed and its pose was 
compared to that of the crystallographic structure. 
In table 1 are reported docking score values for all studied compounds and for each 
protein structure used. Results obtained for Vinca alkaloids binding site (pdb 1Z2B) 
were not shown because any possible pose was generated by Glide.  
Compounds in table 1 were divided in four groups:  
1. Compounds without side chains (yellow) 
2. Compounds with side chains on the carbonyl group (green) 
3. Compounds with side chains on the pyridine ring (blue) 
4. Compounds with side chains on the pyridine ring and on the carbonyl group 
(ligh blue)  
Cmp 
4O4I 
Epot
a
 
4O4I 
Laul
a
 4O2B
a
 
14a -3.992 -4.808 -5.177 
14i -4.548 -4.911 -5.421 
16a -4.044 -5.028 -5.338 
16i -4.592 -5.007 -5.15 
17a -4.824 -4.941 -4.714 
17b -5.604 -4.597 -5.631 
18a -4.759 -4.899 -5.591 
    14b -6.648 -5.357 -5.759 
14c -5.299 -5.843 -6.346 
14d -5.976 -5.918 -6.63 
14e -5.379 -5.783 -5.808 
14f -7.078 -6.511 -7.17 
14g -6.987 -5.777 -7.323 
14h -5.504 -3.721 -6.664 
14j -4.861 -5.111 -5.790 
14k -5.211 -4.993 -5.252 
14l -5.961 -5.582 -6.236 
14m -5.241 -4.542 -5.822 
14n -6.415 -5.266 -6.407 
14o -6.856 -5.313 -5.582 
14p -5.563 -5.633 -6.215 
16b -5.173 -6.153 -6.137 
16c -5.884 -6.838 -7.329 
16d -5.98 -7.025 -7.173 
16e -5.491 -7.061 -7.096 
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 Cmp 
 
4O4I 
Epot
a
 
 
 
4O4I 
Laul
a
 
 
 
   
   4O2B
a
 
16f -6.61 -6.963 -7.25 
16g -5.351 -7.139 -7.565 
16h -5.783 -6.504 -4.694 
16j -6.123 -5.446 -6.575 
16k -5.915 -6.284 -6.977 
16l -5.847 -5.331 -6.636 
16m -5.122 -5.796 -6.316 
16n -5.856 -6.778 -4.614 
16o -6.982 -6.148 -6.303 
16p -5.7836 -5.067 -6.413 
17c -5.985 -5.571 -5.320 
17d -6.404 -6.153 -7.243 
17e -6.129 -4.932 -6.258 
17f -5.986 -5.846 -6.768 
17g -6.393 -5.673 -6.755 
17h -6.920 -6.297 -5.211 
17i -5.731 -4.484 -3.418 
17j -5.877 -4.692 -4.694 
17k -6.176 -4.742 -6.182 
17l -5.807 -4.818 -6.339 
17m -6.549 -3.674 -4.930 
17n -6.987 -5.333 -6.407 
17o -6.074 -5.777 -7.119 
17p -5.978 5.964 5.556 
18b -6.534 -4.894 -5.509 
18c -6.691 -5.652 -6.732 
18d -6.604 -5.687 -6.755 
18e -6.397 -5.754 -5.818 
18f -7.724 -4.773 -7.373 
18g -7.796 -4.607 -5.624 
18h -6.619 -5.971 -5.413 
    15a -8.28 -6.097 -5.328 
15b -6.132 -6.483 -6.483 
15c -6.355 -5.888 -6.673 
15d -6.269 -7.275 -6.051 
15e -6.586 -6.432 nd
b
 
15f -6.666 -6.412 nd
b
 
15g -6.009 -7.131 -5.694 
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Cmp 
4O4I 
Epot
a
 
4O4I 
Laul
a
 
 
4O2B
a
 
15h -6.735 -5.766 -5.619 
15i -6.405 -5.956 -5.259 
15j -6.111 -6.534 -3.355 
15k -6.42 -6.613 -5.353 
15l -6.893 -5.508 nd
b
 
15m -6.188 -6.069 -3.85 
15n -6.009 -7.131 -5.694 
    
a Glide Docking Score values 
b nd: not docked compounds 
red: best docking score values 
 
Table 1 Docking results of compounds 14-18. 
Analysing the docking score results is possible to notice that many compounds show 
good score values in particular for the Cochicine binding site (4O2B). Better results 
were obtained for compounds bearing side chains on the carbonyl group, in which a 
significant improvement is observed comparing docking score values of the first and 
second group. 
The best results are showed by compounds bearing side chains with hydrogen-acceptor 
groups (ex. compounds 14f and 14g with docking score values of -7.17 and -7.32 
respectively; compounds 16f and 16g with docking score values of -7.25 and -7.56 
respectively) responsible for specific interactions with Colchicine binding site, in 
particular with Asn350 residue. 
Compounds of the third groups showed good docking score values but without 
selectivity towards a specific binding site. 
Compounds of the fourth group, bearing side chains on the pyridine ring and on the 
carbonyl group, show better docking score values for Taxanes binding site (4O4I) 
(wider than colchicine binding site), probably because of their steric hindrance caused 
by the presence of both side chains. 
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RESULTS AND DISCUSSIONS: CHEMISTRY 
 
Through few steps it was possible to obtain the desired tripentones (14,16)a in good 
yields (50-54%).  The key intermediate for the synthesis of these pyrido-pyrrolizinones 
are respectively 3-aminoester 21a and 2-aminoester 22a. 
 
 
These key esters were obtained in good yields (70-83%) from commercial ortho-
aminopyridine carboxylic acids of type (19,20)a, through Fischer esterification with 
concentrated sulfuric acid in absolute ethanol at reflux for 48 hours
43
 (Scheme 1).  
 
Scheme 1 
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The following pyrrolation on the amino group of amino-esters (21,22)a under Clauson-
Kaas conditions in the presence of 2,5-dimethoxytetrahydrofuran, 4-chloropyridine 
hydrochloride in anhydrous 1,4-dioxane at reflux gave intermediates (23,24)a in 
excellent yields (89-92%).  
 
 
Scheme 2 
Through condensation of 2,5-dimethoxytetrahydrofuran on our primary amino group, 
following intermolecular attack on the carbonyl function and final dehydration, we 
obtained desired pyrrole in derivatives (23,24)a (Scheme 2). 
These intermediates were later converted to the corresponding amides (25,26)a. The 
first attempt was made in refluxing pyrrolidine in ratio up to 1:42 for 36 hours. The 
reaction of amidation worked but the desired amides were obtained in low yields (38-
42%). We decided to try a different method via carboxylic acid, by using activating 
agents of the carboxylic function such as N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) and hydroxy-benzotriazole (HOBt). Indeed 
corresponding carboxylic acids were obtained by hydrolysis of the ester groups under 
basic condition, lithium hydroxide in ethanol at reflux for 4 hours. Following amidation 
with pyrrolidine, in presence of EDC and HOBt, at room temperature for one night, 
afforded to the desired amides (25,26)a. This “strategy” allowed us to isolate the desired 
derivatives from good to high yields (54-88%) and in short time (16 hours).  
Cyclization of these latter was performed by acylation under Vilsmeier-Haack 
conditions followed by alkaline treatment. As difference of classic Vilsmeier-Haack 
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acylation, pyrrolidinecarboxamides (25,26)a take the place of dimethylformamide 
(DMF) that is the common formylating reagent used in this reaction
13
.  
By treatment of these amides with phosphorous oxychloride (POCl3) we obtained an 
intermediate iminium salt that was subsequently hydrolyzed in alkaline conditions  
(NaOH 10%) to give the tripentones (14,16)a (Scheme 3). 
 
Scheme 3  
These latter, isolated in good yields (50-54%), were used for the following reaction of 
substitution with suitable heteroaryl carbohydrazide side chains to give derivatives of 
type (14,16)b-h (Scheme 4 and 5) (Table 2 and 3). 
 
Scheme 4 
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Compound          Aryl Yield 
14b Pyridin4-yl 49% 
14d Furan-2-yl 62% 
14e Thiophen-2-yl 50% 
14h Benzoyl 56% 
  
16b Pyridin4-yl 51% 
16d Furan-2-yl 87% 
16e Thiophen-2-yl 49% 
16h Benzoyl 71% 
Table 2 
 
In the first attempt we used the same conditions described from Grande et al. for the 
synthesis of N’-heteroacyl-9H-pyrrolo[1,2-a]indol-9-hydrazones 1322. Therefore, 
tripentone 16a was reacted with isonicotinohydrazide 27b in a mixture of ethanol and 
toluene (1:3) at reflux for 36 hours. We isolated the desired compound 16b but in too 
low yield (25%). We decided to try again this reaction, using only toluene as solvent of 
reaction and Dean-Stark apparatus to remove water that is produced during this 
reaction. This time we had got better yield (51%) and lower time of reaction (24 hours 
vs 36 hours) than the first attempt. This latter method was used also to prepare in 
moderate yield derivate 14b (49%) by reaction between tripentone 14a and 
isonicotinohydrazide 27b. In the same conditions reaction between tripentones (14,16)a 
and 2-furan-2-carboxylic acid hydrazide 27d gave the corresponding derivatives 14d 
(62%) and 16d (87%); reaction with 2-thiophenecarboxylic acid hydrazide 27e gave the 
derivatives 14e (50%) and 16e (49%). Reaction from the same tripentones with 
benzhydrazide 27h afforded the last final compounds 14h (56%) and 16h (71%).  
Tripentones (14,16)c,f,g (Table 3) (40-88%) were obtained by refluxing for 24 hours in 
ethanol of the tripentones (14,16)a with nicotinic hydrazide 27c, 4-aminobenzhydrazide 
27f and 4-hydroxybenzhydrazide 27g respectively  (Scheme 5).  
In this case we preferred to use ethanol instead of toluene, since we observed that when 
the reaction was run by using ethanol as solvent, a precipitation of the desired products 
occurred.  
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Scheme 5 
 
 
Compound Aryl Yield 
14c Pyridin-3-yl 88% 
14f 4-Aminobenzoyl 40% 
14g 4-Hydroxybenzoyl 80% 
 
 
 
 
16c Pyridin-3-yl 60% 
16f 4-aminobenzoyl 45% 
16g 4-hydroxybenzoyl 85% 
 
Table 3 
 
In order to isolate tripentones (14,16)i first we used the same synthetic route reported 
for derivatives (14,16)a (Scheme 1), but this time we started from common 
intermediates amino-esters (21,22)a (Scheme 6). 
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Scheme 6 
Bromuration of these amino-esters, performed with bromine in acetic acid at room 
temperature, afforded to the bromo-derivatives of type (21,22)b in good or excellent 
yields (51-100%). Next steps of pyrrolation, amidation and final cyclization were 
performed in the same conditions described above for the previous series.  The new 
tripentone 16i was reacted with heteroaryl carbohydrazides 27b-h to give the 
derivatives 16j-p (Table 4) in yields from 35% to 93%, using toluene as solvent of 
reaction for compounds 16j,l,m,p, whereas ethanol for  tripentones 16k,n,o (Scheme 7). 
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Scheme 7   
 
 
 
 
Compound Aryl Yield 
16j      Pyridin-4-yl   40% 
 16k      Pyridin-3-yl          63% 
16l      Furan-2-yl   45% 
         16m               Thiophen-2-yl                74%   
 16n  4-aminobenzoyl      52% 
 16o     4-hydroxybenzoyl      93% 
         16p                 Benzoyl                          35% 
Table 4 
 
From the tripentone 14i we could obtain different series of compounds, such as 
tripentones with heteroaryl carbohydrazide side chains on the carbonyl group (14j-p), 
tripentones with heteroaryl carbohydrazide side chains on the bromine (15a-g), because 
this position of halogen on pyridine ring is able to give SNAr, and finally tripentones 
with heteroaryl carbohydrazide side chains on both carbonyl group and bromine (15h-n) 
(Scheme 8).   
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Scheme 8 
 
Unfortunately we couldn’t isolate any compounds of these three series, despite we tried 
several times. 
In the first attempt tripentone 14i was reacted with isonicotinohydrazide 27b, using 
toluene as solvent of reaction and Dean-Stark apparatus, at reflux for 24 hours (Scheme 
9). At beginning we used 1eq of our starting material and another one of carbohydrazide 
chain, the same conditions used in the other series, but it wasn’t enough. We decided to 
increase equivalents of chain from (1:1) to (1:3) until (1:5) but also in these cases we 
didn’t obtain the desired compound. Indeed, the reaction mixture became really dirty 
and no priority spot was available to isolate.  
 
 
Scheme 9 
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Another attempt was conducted from tripentone 14i and 4-hydroxybenzohydrazide 27g 
(Scheme 9), but the reaction followed the same path of the one described above. Indeed, 
also in this case we didn’t obtain the desired compound. 
The synthetic route planned to obtain 4- or 6-azaindoles 17-18 identified the key 
intermediates in 4-azaindole-2-amino-3-esters 32a or 32b and 6-azaindole-2-amino-3-
ester 33a. 
 
 
We started to synthesize intermediates 30a-b and 31a by reaction between the 
opportune commercial chloro-3-nitropyridines 28a-b, 29a with potassium enolate of 
ethyl cyanoacetate in t-butanol at reflux for 12 hours (Scheme 10)
44,45
.  
 
Scheme 10 
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These latter, isolated in high to excellent yields (75-100%), were reduced with iron in 
acetic acid at room temperature to the corresponding key intermediates 32a-b, 33a (79-
88%). 
We had several synthetic problems to afford derivatives 17a-b and 18a (Scheme 10). 
Different attempts were conducted to optimize this synthetic route.  
Regarding the final tripentone 17b we could obtain intermediates 30b (75%), 32b 
(79%) and also, under Clauson-Kaas conditions, compound 34b in good yield (65%). 
Following amidation reaction tried in refluxing pyrrolidine (1:42) for 24 hours, didn’t 
allowed the isolation of desired product. The reaction mixture was really dirty without a 
priority spot to isolate and there was still starting material unreacted. We tried to obtain 
the corresponding amide, by hydrolysis of the ester group under basic condition, 
followed by amidation with pyrrolidine, using activating agents the carboxylic function 
such as EDC and HOBt (Scheme 11).  
 
 
Scheme 11 
 
Unfortunately, we found more complications to hydrolyze compound 34b. In fact 
different attempts were made: using a 5% NaOH solution at reflux for 18 hours; 20% 
KOH  solution at reflux for 24 hours; pellets of potassium hydroxide (1:11) in ethanol at 
reflux for 24 hours; or with lithium hydroxide (1:10) in ethanol at reflux for the same 
time. Finally, we used lithium hydroxide (1:10) in a mixture of methanol and water 
(4:1) at reflux for 30 hours. Even changing different conditions such as solvents, bases 
and times of reaction, none of these attempts worked and we couldn’t obtain desired 
carboxylic acid. 
Another idea was to obtain the corresponding acyl halide, function more reactive than 
ester (34b), but the problem was the same. We didn’t obtain desired carboxylic acid to 
convert into corresponding acyl halide and then into amide 36b. 
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Finally, we thought to invert reaction’s order, because most likely pyrrole ring, formed 
during Clauson-Kaas reaction, inhibited the amidation of our ester for steric hindrance. 
Actually, we tried to carry out first amidation in refluxing pyrrolidine (1:42) for 24 
hours and then to carry out Clauson-Kaas reaction. Unfortunately, also this attempt 
didn’t work due to the amidation step. 
 
Regarding final tripentones 17a and 18a, we obtained in excellent yields (80-100%) 
derivatives (30-31)a and (32-33)a (85-88%) but we couldn’t isolate following 
compounds (34-35)a (Scheme 12). Indeed, even changing different conditions such as 
amount of reagents, temperature, and times of reaction (Table 5), unfortunately, we 
didn’t afford the desired intermediates. 
 
 
Scheme 12 
Derivate 2,5-dimethoxy-
THF 
4-Chloropyridine 
hydrochloride 
Temperature Result 
32a 1 eqv 1 eqv Reflux, 4h Side products 
33a 1 eqv 1 eqv Reflux, 4h Side products 
32a 2 eqv 2 eqv Reflux, 5h Side products 
33a 2 eqv 2 eqv Reflux, 5h Side products 
32a 1 eqv 1 eqv Rt50°C, 1h Side products 
33a 1 eqv 1 eqv Rt50°C, 1h Side products 
Table 5 
From NMR data we understood that more probably Clauson-Kaas reaction didn’t work 
for the presence of the free NH in the aza-indole ring. We decided to try a methylation 
in this position (Scheme 13), using potassium t-butoxide as base,  tris[2-(2-
methoxyethoxy)ethyl]amine (TDA-1) (1 or 2 drops) as phase transfer catalyst and 
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methyl iodide as methylating agent in toluene at room temperature. Unfortunately, this 
reaction didn’t bring us to any result as there wasn’t a priority spot to isolate in the 
reaction mixture. Therefore, we thought to carry on the methylation under nitrogen 
atmosphere and to use cesium carbonate as base and DMF as solvent of reaction. Also 
in this case we had the same result.  
 
 
Scheme 13 
 
We also thought to try a diazotization of amino group in acetic acid with stoichiometric 
amount of sodium nitrite under nitrogen atmosphere in the dark, followed by addition of 
aqueous sodium carbonate
44,45 
(Scheme 14). In these reactions is crucial the strict 
control of temperature at 0°C both during diazotization and neutralization to obtain 
desired compounds in high yields.  
Diazo compounds (40-41)a were treated with tetrafluoroboric acid in diethyl ether to 
give corresponding tetrafluoroborate derivatives (42-43)a. The crude of these latter 
intermediate compounds was taken up onto the next step of nucleophilic substitution 
with pyrrole, previously activated for treatment with a base, in dry DCM to afford the 
desired intermediates (34-35)a. Unfortunately, also this attempt failed in both series. 
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Scheme 14 
Another synthetic route was planned starting from the same starting materials (Scheme 
15). In the new route we tried to obtain 2-aminoazaindole-3-carboxamide (45-46)a by 
reaction between 1-(cianoacetyl)-pyrrolidine 44 and opportune 2- or 4-chloro-3-
nitropyridines (28-29)a. Through following Clauson-Kaas reaction and final cyclization 
under Vilsmeier-Haack conditions we would have wanted to get final tripentones (17-
18)a. 
 
 
Scheme 15 
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In the first step, sodium hydride (in excess) was added to a solution of 1-(cianoacetyl)-
pyrrolidine 44 in DMF and then opportune 2- or 4-Cl-3-nitropyridines (28-29)a was 
added. Only when the SNAr reaction was completed, a solution 1 N HCl was added to 
neutralize the excess of sodium hydride, and the intermediate was reduced to desired 
amino-azaindole with FeCl3 and Zn
46
 (Scheme 16).  
 
Scheme 16 
We obtained only the 2-chloro-3-aminopyridine at place of 2-amino-azaindole-3-
carboxamide 45a because the reaction illustrated in scheme 16 didn’t work for 4-
azaindole’s series.  
 
Scheme 17 
37 
 
Regarding the 6-azaindole’s series, we obtained the desired carboxamide 46a (30%) and 
the Clauson-Kass’s product 37a (55%) as well. Unfortunately, the cyclization didn’t 
work (Scheme 17). Even increasing amount of POCl3 or changing temperature (reflux 
instead 70°C) we didn’t isolate desired final tripentone 18a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
RESULTS AND DISCUSSION: BIOLOGY  
All tripentones synthesized 14a-i and 16a-p (Table 6) were submitted to biological 
laboratory of “Dipartimento di Scienze e Tecnologie Biologiche Chimiche e 
Farmaceutiche” (STEBICEF) University of Palermo in collaboration with Professor L. 
Tesoriere with the aim of evaluating their antitumoral activity.  
 
 
 
 
Compound R W Yield 
14a H O 50% 
14b H N-NH-CO-Pyridin-4-yl 49% 
14c H N-NH-CO-Pyridin-3-yl 88% 
14d H N-NH-CO-Furan-2-yl 62% 
14e H N-NH-CO-Thiophen-2-yl 50% 
        14f H N-NH-CO-4-NH2-C6H4 40% 
14g H N-NH-CO-4-OH-C6H4 80% 
14h H N-NH-CO-C6H5 56% 
        14i Br O 40% 
   
16a H O 54% 
16b H N-NH-CO-Pyridin-4-yl 51% 
16c H N-NH-CO-Pyridin-3-yl 60% 
16d H N-NH-CO-Furan-2-yl 87% 
16e H N-NH-CO-Thiophen-2-yl 49% 
16f H N-NH-CO-4-NH2-C6H4 45% 
16g H N-NH-CO-4-OH-C6H4 85% 
16h H N-NH-CO-C6H5 71% 
        16i Br O 61% 
        16j Br N-NH-CO-Pyridin-4-yl 40% 
16k Br N-NH-CO-Pyridin-3-yl 63% 
        16l Br N-NH-CO-Furan-2-yl 45% 
        16m Br N-NH-CO-Thiophen-2-yl 74% 
        16n Br N-NH-CO-4-NH2-C6H4 52% 
        16o Br N-NH-CO-4-OH-C6H4 93% 
        16p Br N-NH-CO-C6H5 35% 
Table 6 
Preliminary biological screening were performed on derivatives 14a-b,g,i and 16a-p on 
HCT116 colorectal carcinoma cells. Cell monolayers were incubated for 72 hours in the 
absence (control) or in the presence of the compounds at the indicated concentrations 
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and cell growth was assessed by MTT test as reported in the methods section. This 
assay is based on reduction of the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), into its insoluble formazan crystals (purple 
precipitate) by NADH-dependent cellular oxidoreductase enzymes (Figure 13). 
The absorbance of this colored solution can be quantified by spectrophotometry and it is 
directly proportional to cell viability. In fact, when the cells die, they lose the ability to 
convert MTT into purple colored Formazan product
47
.  
 
 
Figure 13 Structures of MTT and Formazan product 
 
In the figure 14 is possible to discern the effect of the different tripentone derivatives on 
the cell growth (tumor cells line HCT116). In greater detail it is showed the activity of 
not substituted tripentones (14A), tripentones substituted with isonicotinohydrazide and 
nicotinic hydrazide side chains (14B), tripentones substituted with 2-furan-2-carboxylic 
acid hydrazide and 2-thiophenecarboxylic acid hydrazide side chains (14C), tripentones 
substituted with 4-aminobenzhydrazide and 4-hydroxybenzhydrazide side chains (14D) 
and tripentones substituted with benzhydrazide side chain (14E) respectivelty (Figure 
14). Results are indicated as the percentage of viable cells with respect to untreated 
controls. Values are the mean±SD of three separate experiments in triplicate. 
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Figure 14 Effect of tripentone derivatives on the growth of human intestinal tumor cells line HCT116. 
From these first results was possible to note that tripentones substituted result most 
active than not substituted ones in general. This data was in agreement with our original 
idea, indeed the introduction of heteroaryl carbohydrazide side chains increases anti-
proliferative effect of our compounds and above all offers a possibility of forming 
conjugate salts to improve water solubility and thereby their pharmacokinetic 
properties. 
Moreover, was interesting to note how the series 16 are better than 14 one in terms of 
activity. In fact, the most active compounds against HCT116 were 16e, 16g, 16j, 16l 
and 16n-p with in vitro anti-proliferative activity in the micro-submicromolar range 
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(Table 7). In particular, in the environment of 16’ series the presence of bromine on the 
pyridine ring (position 3) appears crucial for confering good activity to the 5H-
pyrido[3,2-b]pyrrolizin-5-ones derivatives. Indeed, the best compounds were 16j, 16l 
and 16n, having GI50 values of 0.110.01 M, 0.170.02 M and 0.230.02 M 
respectively. Cytotoxicity of 16e, 16g, 16j, 16l and 16n-p was also assessed on MCF-7 
cell line (human breast cancer) and the calculated GI50 values are reported in Table 7. 
 
        GI50SD 
  
                                                             HCT116               MCF7    
 
   16e  0.460.05     3.150.29  
   16g  2.540.16     16.111.45 
     16j  0.110.01     3.400.35 
   16l  0.170.02     1.610.98 
   16n  0.230.02     1.800.15 
   16o  1.660.18     15.621.11 
   16p  1.740.12     14.881.03 
                                         
a
GI50 is the molar concentration of the compound that 
                                         inhibits 50% net cell growth. Values are the meanSD 
                                         of three separate experiments carried out in triplicate 
 
Table 7 GI50 values (M) for the in vitro anti-proliferative activity of the most active tripentone 
derivatives, determined by MTT test on HCT116 and MCF7 cells after 72 h treatment. 
 
 
It can be observed that, although all tripentones inhibit the growth of tumor cells of 
breast cancer, their anti-proliferative efficacy appeared about one order of magnitude 
lower than that shown towards the cells of the colon rectal cancer HCT116. 
We also investigated alterations in the cell cycle caused by tripentones 16e (the most 
active compound without bromine on the pyridine ring) and 16j (the most active 
compound with bromine on the pyridine ring) in colorectal cancer cells (Figure 15). 
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With the aim to discriminate cells in different phases of the cell cycle, flow cytometric 
analysis of nuclear DNA content after 24 hours treatment of HCT-116 cells was 
determined using propidium iodide (PI) 47. The percentage of cells in the different 
phases of the cycle was calculated by Expo32 software. Values are the meanSD of 
three separate experiments in triplicate.  
Propidium iodide (PI) 47 is a DNA-binding dye by intercalating between the bases. It is 
the most commonly used dye to quantitatively assess DNA content as PI is 
stoichiometric, it binds in proportion to the amount of DNA present in the cell. 
 
 
 
Differentiation between phases of the cell cycle is based on the content of genetic 
material, which in non-dividing cells is limited to one copy of DNA. The cell 
population in the S phase (DNA replication phase) is synthesizing genetic material, and 
thus contains more DNA than quiescent cells. The subsequent G2/M phase 
(interphase/mitosis) is characterized by the presence of two copies of DNA. At last, 
cells in the region subdiploid are considered as an index of apoptosis. Therefore, the 
alterations in these phases are used as a basis for the comparison of different treatments.  
Both 16e and 16j caused a significant dose-dependent decrease in the percentage of 
cells in the G0/G1 and S phases, accompanied by a concomitant percentage increase of 
cells in the G2/M phase, and appearance of a subG1-cell population (Figure 15). These 
results indicated that antiproliferative mechanism induced by the compounds is in the 
process of separation of the chromatids. 
 
 
43 
 
 
 
 
 
 
 
Figure 15 Effect of 16e and 16j on the cell cycle distribution of HCT116 colorectal cancer cells.  
 
To determine whether HCT-116 cells undergo apoptosis upon treatment with the 
tripentone analogues, cells were treated with 16e or 16j for 24 hours, stained with both 
propidium iodide (PI) 47 and Annexin V-Fluorescein isothiocyanate (FITC), and 
analyzed by flow cytometry. Through this assay we aimed to evaluate the 
externalization of the Phosphatidylserine (PS) on the external cellular environment. In 
fact, during the earlier phases of apoptosis the phosphatidylserine is translocated from 
the inside to the outside of the cytoplasmatic membrane. Annexin V has high selectivity 
toward PS and it can be conjugated with fluorochromes such as Fluorescein 
isothiocyanate (FITC). The complex Annexin V-FITC binds with high affinity PS. For 
this reason, the Annexin V-FITC assay can be used to notice cells that are undergoing 
apoptosis. In order to distinguish early, late apoptosis or necrosis staining with FITC 
Annexin V is usually used in combination with a vital dye such as propidium iodide (PI) 
47, indeed PI doesn’t permeate inside of viable cells. 
In particular, we can discern:  
 viable cells in which Annexin V-FITC and PI are negative; 
 early apoptosis cells in which Annexin V-FITC is positive instead PI is negative; 
 late apoptosis cells in which annexin V-FITC and PI are positive; 
 necrotic cells in which Annexin V-FITC is negative instead PI is positive. 
 
 
 
0
25
50
75
100
%
 E
ve
n
ts G2/M
S
G0/G1
subG0
               Control       5 M        10 M        5 M         10 M     
                                               16j             16e 
 
 
44 
 
 
 
 
 
 
 
 
Figure 16 Cell apoptosis by 16e and 16j in HCT116 cells. Percentage of Annexin V/propidium iodide 
(PI) double-stained cells, as determined by flow cytometry. Control, cells treated with vehicle; cells were 
treated for 24 h with either tripentone derivatives. Representative images of three experiments with 
comparable results. 
 
As shown in figure 16 none of the compouds exerted necrotic effects on HCT116 cells, 
while inducing a clear pro-apoptotic effect with an high percentage of cells shifted 
towards early apoptosis. 
 
 
 
 
  
   
          Control                   16e (5M)         16j (5M)  
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CONCLUSION  
In conclusion we reported: 
 two series of new tripentones 14a-i and 16a-p were completed and synthesized; 
 the new compounds showed anti-proliferative activity in micro or sub-
micromolar range; 
 the new tripentones showed the best activity against HCT-116 colorectal 
carcinoma cells; 
 alterations in the cell cycle caused by tripentones 16e (the most active 
compound without bromine on the pyridine ring) and 16j (the most active 
compound with bromine on the pyridine ring) were investigated in colorectal 
cancer cells (HCT-116); 
 both 16e and 16j caused a significant dose-dependent decrease in the percentage 
of cells in the G0/G1 and S phases, accompanied by a concomitant percentage 
increase of cells in the G2/M phase, and appearance of a subG1-cell population; 
 Annexin V-FITC assay was assessed with the aim to determine whether HCT-
116 cells undergo apoptosis upon treatment with the tripentones 16e and 16j; 
 derivatives 16e and 16j induced a clear pro-apoptotic effect with an high 
percentage of cells shifted towards early apoptosis; 
 all these data are in agreement with our original idea to synthesize potential 
antitubulin agents. However, other ongoing studies aim to better define the 
pharmacological profile and the mechanism of action of our tripentones. 
 It might be interesting to perfom a structure–activity relationship study (SAR) to 
evaluate the effect of different halogens on tripentone (position 3) with the aim 
to understand if the presence of bromine increases the activity of our compounds 
due either its lipofilicity (Br > Cl > F) or its electronic effects (F > Cl > Br). 
Morover, since the most active compounds are decorated with isonicotinic 
hydrazide (16j), 2-furan-2-carboxylic acid hydrazide (16l) and 4-
aminobenzhydrazide (16n) side chains it might be interesting also to evaluate 
the introduction of different substitutes (polar, apolar, small or big) on the 
terminal ring of the side chains.  
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EXPERIMENTAL SECTION 
CHEMISTRY 
General methods 
All melting points were taken on a Buchi-Tottoly capillary apparatus and were 
uncorrected. IR spectra were determined in bromoform with a Shimadzu FT / IR 8400S 
spectrophotometer. 
1
H and 
13
C NMR spectra were measured at 200 and 50 MHz, 
respectively, on DMSO-d6 or CDCl3 solution, using a Bruker Avance II series 200 MHz 
spectrometer. Chromatography column was performed with MERK silica gel 230-400 
mesh ASTM or FLASH40i Biotage chromatography or with Buchi Sepacore 
chromatography module (prepacked cartridge reference). Elementar analyses (C, H, N) 
were within ±0.4% of the theoretical values. 
Pyridines’ series: 
Synthesis of aminopyridine-carboxylates (21-22)a: 
To a solution of suitable aminopyridine-carboxylic acid (19-20)a (1.0 g, 7.25 mmol) in 
absolute ethanol (4.07 mL), at 0°C, was slowly added concentrated H2SO4 (1.25 mL, 
23.5 mmol) and the reaction mixture was heated to reflux for 48 hours. After cooling, 
the mixture was concentrated and poured into ice. The mixture was basified with 
concentrated aqueous ammonia to pH 8-9 and the white precipitate formed was 
collected by filtration. The filtrate was extracted with diethyl ether (4 × 10 mL), the 
organic layer was washed with brine (40 mL), dried over anhydrous Na2SO4, filtered 
and evaporated. This crude was combined with that from the above filtration and the 
whole was purified by silica gel column cromatography  (Petroleum Ether:Ethyl acetate, 
8:2) to give the desired esters (21-22)a.  
Ethyl 3-aminopyridine-2-carboxylate (21a)
 43
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Yield: 70%, off-white solid; mp: 129.9-130.3°C; IR: 3491 – 3374 (NH2), 1689 (CO) 
cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 8.08 (1H, dd, J = 4.2, 1.4 Hz, H-6), 7.27-7.19 (1H, 
dd, J = 8.3, 4.2 Hz, H-5), 7.04 (1H, dd, J = 8.4, 1.4 Hz, H-4), 5.76 (2H, bs, NH2), 4.45 
(2H, q, J = 7.1 Hz, CH2), 1.45 (3H, t, J = 7.1 Hz, CH3); 
13
C NMR (50 MHz, CDCl3) δ: 
167.6 (s), 146.9 (s), 138.7 (d), 128.1 (s), 127.9 (d), 124.8 (d), 61.3 (t), 14.4 (q). Anal. 
Calculated for C8H10N2O2 (MW: 166.18): C, 57.82; H, 6.07; N, 16.86%. Found: C, 
57.75; H, 6.26; N, 16.82%. 
Ethyl 2-aminopyridine-3-carboxylate (22a): 
 
Yield: 83%, white solid; mp: 112.9-113.3°C; IR: 3501 – 3370 (NH2), 1689 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.20 (1H, dd, J = 5.2, 2.0 Hz, H-6), 8.05 (1H, dd, J 
= 8.2, 1.0 Hz, H-4), 7.17 (2H, bs, NH2), 6.62 (1H, dd, J = 8.2, 5.2 Hz, H-5), 4.28 (2H, q, 
J = 6.8 Hz, CH2), 1.32 (3H, t, J = 6.8 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 
166.5 (s), 159.4 (s), 153.9 (d), 139.6 (d), 111.8 (d), 104.6 (s), 60.4 (t), 14.1 (q). Anal. 
Calculated for C8H10N2O2 (MW: 166.18): C, 57.82; H, 6.07; N, 16.86%. Found: C, 
57.92; H, 6.17; N, 16.66%.  
 
Synthesis of amino-bromopyridine-carboxylates (21-22b): 
Bromine (0.08 mL, 1.56 mmol) solubilized in glacial acetic acid (0.33 mL) was added 
dropwise to a solution of suitable aminoester (21-22)a (0.2 g, 1.2 mmol) in glacial 
acetic acid (0.7 mL). The reaction mixture was vigorously stirred at room temperature 
for 1 hour. A small amount of water (3 mL) was added, and the precipitate formed 21b 
was collected by filtration. Instead in the case of derivative 22b, the solution was 
extracted with ethyl acetate (3 x 10 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo. The crude was purified by silica gel column cromatography 
(DCM:Ethyl Acetate, 9:1) to afford compound 22b.  
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Ethyl 3-amino-6-bromopyridine-2-carboxylate (21b):  
 
Yield: 51%, yellow solid; mp: 131.0-131.3°C; IR: 3488 – 3375 (NH2), 1689 (CO)  cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.30 (1H, d, J = 2.6 Hz, H-4), 8.12 (1H, d, J = 2.6 
Hz, H-5), 7.37 (2H, bs, NH2), 4.28 (2H, q, J = 7.1 Hz, CH2), 1.32 (3H, t, J = 7.1 Hz, 
CH3); 
13
C NMR (50MHz, DMSO- d6) δ:165.9 (s), 147.6 (s), 132.4 (d), 128.7 (d), 125.5 
(s), 124.3 (s), 60.5 (t), 14.2 (q). Anal. Calculated for C8H9 BrN2O2 (MW: 245.07): C, 
39.21; H, 3.70; N, 11.43%. Found: C, 39.01; H, 3.57; N, 11.23%.  
Ethyl 2-amino-5-bromopyridine-3-carboxylate (22b): 
 
Quantitative yield, light yellow solid; mp: 140.0-140.5°C; IR: 3500 – 3374 (NH2), 1689 
(CO)  cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.29 (1H, d, J = 2.5 Hz, H-6), 8.12 (1H, 
d, J = 2.5 Hz, H-4), 7.41 (2H, bs, NH2), 4.28 (2H, q, J = 7.1 Hz, CH2), 1.30 (3H, t, J = 
7.1 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 165.3 (s), 157.9 (s), 153.9 (d), 141.0 
(d), 106.3 (s), 103.9 (s), 60.9 (t), 13.9 (q). Anal. Calculated for C8H9 BrN2O2 (MW: 
245.07): C, 39.21; H, 3.70; N, 11.43%. Found: C, 39.31; H, 3.87; N, 11.54%. 
 
Synthesis of (1H-pyrrol-1-yl)pyridine-carboxylates (23-24)a,b: 
To a solution of 2,5-dimethoxytetrahydrofuran (0.23 mL, 1.81 mmol) in anhydrous 1,4-
dioxane (21.4 mL), was added 4-chloropyridine hydrochloride (0.27 g, 1.81 mmol) and 
the reaction mixture was stirred at room temperature for 15 minutes. Appropriate 
derivate (21-22)a,b (1.81 mmol) was added and the reaction mixture was heated to 
reflux for 18 hours. Upon cooling a precipitate formed that was filtered. The solid was 
discarded, while the mother liquor containing the title compound was evaporated in 
vacuo and used into the next step without further purification for derivatives 23b and 
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24b. In the case of compounds (23-24)a, the residue was purified by silica gel column 
cromatography, eluting by DCM:Ethyl Acetate, 98:2 (23a) or  Petroleum Ether:Ethyl 
Acetate, 9:1 (24a) to give desired derivative.  
Ethyl 3-(1H-pyrrol-1-yl)pyridine-2-carboxylate (23a): 
  
 
 
Yield: 92%, light yellow oil; IR: 1696 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 8.47 
(1H, dd, J = 4.7, 1.5 Hz, H-6), 7.58 (1H, dd, J = 8.2, 1.5 Hz, H-4), 7.35 (1H, dd, J = 8.2, 
4.7 Hz, H-5), 6.71 (2H, s, H-2’ and H-5’), 6.21 (2H, s, H-3’ and H-4’), 4.14 (2H, q, J = 
7.1 Hz, CH2), 1.08 (3H, t, J = 7.1 Hz, CH3); 
13
C NMR (50 MHz, CDCl3) δ: 165.5 (s), 
147.6 (d), 146.0 (s), 136.1 (s), 134.0 (d), 125.9 (d), 121.6 (d x 2), 110.6 (d x 2), 62.1 (t), 
13.8 (q). Anal. Calculated for C12H12N2O2 (MW: 216.24): C, 66.65; H, 5.59; N, 12.96%. 
Found: C, 66.79; H, 5.30; N, 12.76%. 
 
Ethyl 6-bromo-3-(1H-pyrrol-1-yl)pyridine-2-carboxylate (23b): 
 
Yield: 93%, light brown solid; mp: 123.5-123.9°C; IR: 1734 (CO) cm
-1
; 
1
H NMR (200 
MHz, DMSO- d6) δ: 8.80 (1H, d, J = 2.4 Hz, H-4), 8.44 (1H, d, J = 2.4 Hz, H-5), 7.12 
(2H, t, J = 2.3 Hz, H-1’ and H-4’), 6.29 (2H, t, J = 2.3 Hz, H-2’ and H-3’), 4.24 (2H, q, 
J = 7.1 Hz, CH2), 1.18 (3H, t, J = 7.1 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 
164.6 (s), 151.6 (d), 147.5 (s), 141.7 (d), 121.5 (s), 120.7 (d x 2), 116.3 (s), 110.8 (d x 
2), 62.1 (t), 13.7 (q). Anal. Calculated for C12H11BrN2O2 (MW: 295.13): C, 48.84; H, 
3.76; N, 9.49%. Found: C, 48.49; H, 3.85; N, 9.74%. 
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Ethyl 2-(1H-pyrrol-1-yl)pyridine-3-carboxylate (24a):  
 
Yield: 89%, light yellow oil; IR: 1717 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 
8.64 (1H, dd, J = 4.8, 1.5 Hz, H-6), 8.20 (1H, dd, J = 7.6, 1.5 Hz, H-4), 7.48 (1H, dd, J 
= 7.6, 4.8 Hz, H-5), 7.14 (2H, s, H-2’and H-5’), 6.27 (2H, s, H-3’ and H-4’), 4.22 (2H, 
q, J = 7.0 Hz, CH2), 1.16 (3H, t, J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 
166.0 (s), 151.0 (d), 148.9 (s), 139.9 (d), 121.6 (d), 120.6 (d x 2), 120.3 (s), 110.4 (d x 
2), 61.6 (t), 13.7 (q). Anal. Calculated for C12H12N2O2 (MW: 216.24): C, 66.65; H, 5.59; 
N, 12.96%. Found: C, 66.51; H, 5.75; N, 13.06%. 
 
Ethyl 5-bromo-2-(1H-pyrrol-1-yl)pyridine-3-carboxylate (24b): 
 
Yield: 89%, brown solid; mp: 95.8-96.2°C; IR: 1689 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 8.78 (1H, d, J = 2.4 Hz, H-6), 8.43 (1H, d, J = 2.4 Hz, H-4), 7.12 (2H, t, J 
= 2.1 Hz, H-2’ and H-5’), 6.28 (2H, t, J = 2.1 Hz, H-3’ and H-4’),  4.24 (2H, q, J = 7.1 
Hz, CH2), 1.18 (3H, t, J = 7.1 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 164.6 (s), 
151.6 (d), 147.7 (s), 141.7 (d), 121.5 (s), 120.7 (d x 2), 116.3 (s), 110.8 (d x 2), 62.0 (t), 
13.6 (q). Anal. Calculated for C12H11BrN2O2 (MW: 295.13): C, 48.84; H, 3.76; N, 
9.49%. Found: C, 48.66; H, 3.95; N, 9.60%. 
 
 
Synthesis of Pyrrolidinecarboxamides (25-26)a,b: 
Method A: A solution of (23-24)a,b (1.39 mmol) in pyrrolidine (58.38 mmol, 4.8 mL) 
was heated to reflux for 36 hours. Upon cooling, the reaction mixture was concentrated 
under reduced pressure and the yellow oil was crystallized by diethyl ether and purified 
by silica gel column cromatography using ethyl acetate as eluent. Yield: 38-42%. 
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Method B: To a solution of (23-24)a,b (2.41 mmol) in ethanol (73.2 mL), was added 
lithium hydroxide (0.29 g, 12.0 mmol) and the reaction mixture was heated to reflux for 
4 hours. After cooling to room temperature, the solvent was totally removed under 
reduced pressure. The crude, cooled by adding to ice, was acidified with 6N HCl and 
extracted with DCM (3 x 30 mL), dried over anhydrous Na2SO4, filtered and 
evaporated. The crude was taken up onto the next step.  
To a solution of the crude in THF (36.5 mL) were added hydroxy-benzotriazole (OHBt) 
(0.36 g, 2.64 mmol),  N,N-diisoproprylethylamine (DIPEA) (0.68 mL, 2.64 mmol) and 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (0.34 g, 2.64 
mmol) and the resulting reaction mixture was stirred at room temperature for 10 
minutes. Pyrrolidine (1.0 mL, 12 mmol) was added and the mixture was stirred at room 
temperature for 12 hours. The solvent was removed under reduced pressure and to the 
residue was added an aqueous saturated NaHCO3 solution (20.4 mL). The crude was 
extracted with ethyl acetate (3 x 30 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo. It was purified by silica gel column cromatography eluting by 
DCM:Ethyl Acetate, 75:25 (25a-b) or Petroleum Ether:Ethyl Acetate, 6:4 (26a-b) to 
give desired amide. Yield on two steps: 54-88%.  
 
2-(Pyrrolidin-1-yl)-3-(1H-pyrrol-1-yl)pyridine (25a):  
 
Yield on two steps: 88%, light yellow powder; mp: 117.5-118.0°C; IR: 1623 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.56 (1H, d, J = 4.6 Hz, H-6), 7.99 (1H, d, J = 8.2 
Hz, H-4), 7.60 (1H, dd, J = 8.2, 4.6 Hz, H-5), 7.04 (2H, s, H-2’ and H-5’), 6.28 (2H, s, 
H-3’ and H-4’), 3.41-3.34 (2H, m, CH2), 2.96 (2H, t, J = 6.2 Hz, CH2), 1.74 (4H, quint, 
J = 6.2 Hz, CH2 x 2); 
13
C NMR (50 MHz, DMSO- d6) δ: 146.6 (s), 148.6 (s), 146.9 (d), 
133.2 (s), 132.5 (d), 124.9 (d), 120.9 (d x 2), 110.5 (d x 2), 46.6 (t), 44.9 (t), 25.2 (t), 
23.7 (t). Anal. Calculated for C14H15N3O (MW: 241.29): C, 69.69; H, 6.27; N, 17.41%. 
Found: C, 69.87; H, 6.07; N, 17.29%. 
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6-Bromo-3-(1H-pyrrol-1-yl)pyridin-2-yl](pyrrolidin-1-yl)methanone (25b):  
 
Yield on two steps: 57%, yellow oil; IR: 1640 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- 
d6) δ: 8.75 (1H, d, J = 2.4 Hz, H-4), 8.27 (1H, d, J = 2.4 Hz, H-5), 7.27 (2H, t, J = 2.2 
Hz, H-1’ and H-4’), 6.36 (2H, t, J = 2.2 Hz, H-2’ and H-3’), 3.05-2.98 (2H, m, CH2), 
2.33-2.27 (2H, m, CH2), 1.78-1.72 (4H, m, CH2 x 2); 
13
C NMR (50 MHz, DMSO- d6) δ: 
163.5 (s), 149.9 (d), 145.4 (s), 140.2 (d), 125.5 (s), 119.6 (d x 2), 116.3 (s), 111.2 (d x 
2), 45.5 (t), 45.0 (t), 25.2 (t), 23.8 (t). Anal. Calculated for C14H14BrN3O (MW: 320.18): 
C, 52.52; H, 4.41; N, 13.12%. Found: C, 52.35; H, 4.53; N, 13.19%. 
 
3-(Pyrrolidin-1-yl)-2-(1H-pyrrol-1-yl)pyridine (26a):  
 
Yield on two steps: 54%, light yellow oil; IR: 1616 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 8.56 (1H, dd, J = 4.7, 1.5 Hz, H-6), 7.92 (1H, dd, J = 7.9, 1.5 Hz, H-4), 
7.42 (1H, dd, J = 7.9, 4.7 Hz, H-5), 7. 23 (2H, s, H-2’ and H-5’), 6.29 (2H, s, H-3’ and 
H-4’), 3.41-3.35 (2H, m, CH2), 2.88-2.70 (2H, m, CH2), 1.75-1.67 (4H, m, CH2 x 2); 
13
C 
NMR (50 MHz, DMSO- d6) δ: 165.2 (s), 149.4 (d), 146.4 (s), 138.2 (d), 124.2 (s), 121.5 
(d), 119.6 (d x 2), 110.8 (d x 2), 46.8 (t), 45.37 (t), 25.2 (t), 23.8 (t). Anal. Calculated for 
C14H15N3O (MW: 241.29): C, 69.69; H, 6.27; N, 17.41%. Found: C, 69.53; H, 6.17; N, 
17.69%. 
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5-bromo-2-(1H-pyrrol-1-yl)pyridin-3-yl](pyrrolidin-1-yl)methanone (26b):  
 
Yield on two steps: 62%, light yellow solid; mp: 119.9-120.2°C; IR: 1620 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.70 (1H, d, J = 2.4 Hz, H-6), 8.23 (1H, d, J = 2.4 
Hz, H-4), 7.21 (2H, t, J = 2.3 Hz, H-2’ and H-5’), 6.30 (2H, t, J = 2.3 Hz, H-3’ and H-
4’), 3.41 (2H, t, J = 6.4 Hz, CH2), 2.94-2.85 (2H, m, CH2), 1.72 (4H, quint, J = 6.4 Hz, 
CH2 x 2); 
13
C NMR (50 MHz, DMSO- d6) δ: 163.5 (s), 149.9 (d), 145.4 (s), 140.2 (d), 
125.5 (s), 119.6 (d x 2), 116.3 (s), 111.2 (d x 2), 46.9 (t), 45.5 (t), 25.2 (t), 23.8 (t). Anal. 
Calculated for C14H14BrN3O (MW: 320.18): C, 52.52; H, 4.41; N, 13.12%. Found: C, 
52.71; H, 4.64; N, 13.32%. 
 
Synthesis of -9H-pyrido[2,3-b]pyrrolizin-9-ones (14)a,i: 
A solution of appropriate pyrrolidinecarboxamides (25)a,b (0.95 mmol) in phosphorus 
oxychloride (2.4 mL, 25.65 mmol) was stirred at 70°C for 6-24 hours. After cooling, the 
reaction mixture was concentrated to give iminium salt as black solid. A 10% aqueous 
NaOH solution (6.65 mL) was slowly added to the residue and the reaction mixture was 
stirred at room temperature for 30 minutes (14i) or heated to 65°C for 30 minutes (14a). 
Upon cooling, the dark crude was extracted with ethyl acetate (3 x 15 mL), dried over 
anhydrous Na2SO4, filtered and evaporated in vacuo. It was purified by silica gel 
column cromatography eluting by DCM:Ethyl Acetate, 95:5 (14a) or Ciclohexane:Ethyl 
Acetate, 90:10 (14i) to give desired tripentone.  
 
9H-Pyrido[2,3-b]pyrrolizin-9-one (14a):  
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Conditions: 70°C for 6 hours. Yield: 50%, yellow solid; mp: 187.4-188.4°C; IR: 1722 
(CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.39 (1H, d, J = 4.5 Hz, H-2), 7.98 (1H, 
d, J = 7.9 Hz, H-4), 7.73 (1H, m, H-6), 7.52 (1H, dd, J = 7.9, 4.6 Hz, H-3), 6.96 (1H, d, 
J = 2.5 Hz, H-8), 6.44 (1H, m, H-7); 
13
C NMR (50 MHz, DMSO- d6) δ: 177.7 (s), 147.9 
(s), 146.3 (d), 139.9 (s), 130.2 (s), 127.4 (d), 122.9 (d), 119.0 (d), 116.2 (d), 115.4 (d). 
Anal. Calculated for C10H6N2O (MW: 170.17): C, 70.58; H, 3.55; N, 16.46%. Found: C, 
70.78; H, 3.35; N, 16.16%.  
 
2-Bromo-9H-pyrido[2,3-b]pyrrolizin-9-one (14i): 
 
Conditions: 70°C for 24 hours. Yield: 40%, yellow powder; mp: 161.9-162.4°C; IR: 
1700 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 8.56 (1H, d, J = 2.2 Hz, H-4 ), 8.17 
(1H, d, J = 2.2 Hz, H-3), 7.66 (1H, dd, J = 2.6, 0.7 Hz, H-6), 7.01 (1H, dd, J = 3.7, 0.7 
Hz, H-8), 6.53 (1H, dd, J = 3.7, 2.6 Hz, H-7); 
13
C NMR (50 MHz, DMSO- d6) δ: 175.0 
(s), 154.8 (s), 152.2 (d), 135.1 (d), 132.0 (s), 125.1 (s), 121.1 (d), 117.8 (d), 116.5 (s), 
115.9 (d). Anal. Calculated for C10H5BrN2O (MW: 249.06): C, 48.22; H, 2.02; N, 
11.25%. Found: C, 47.82; H, 2.34; N, 11.55%. 
 
Synthesis of -5H-pyrido[3,2-b]pyrrolizin-5-ones (16)a,i: 
A solution of suitable pyrrolidinecarboxamides (26)a,b (0.51 mmol) in phosphorus 
oxychloride (1.3 mL, 13.78 mmol) was stirred at 70°C for 18 hours. After cooling, the 
reaction mixture was concentrated to give iminium salt as black solid. A 10% aqueous 
NaOH solution (3.6 mL) was slowly added to the residue and the reaction mixture was 
stirred at room temperature for 30 min. Upon cooling, the dark crude was extracted with 
Ethyl Acetate (3 x 15 mL), dried over anhydrous Na2SO4, filtered and evaporated in 
vacuo. It was purified by silica gel column cromatography eluting by Petroleum 
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Ether:Ethyl Acetate, 85:15 (16a), or Ciclohexane:Ethyl Acetate, 99:1 (16i) to give 
desired tripentone.  
 
5H-Pyrido[3,2-b]pyrrolizin-5-one (16a)
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:  
 
Yield: 54%, yellow solid; mp: 132.0-132.3°C; IR: 1696 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 8.40 (1H, dd, J = 5.2, 1.3 Hz, H-2), 7.95 (1H, dd, J = 7.3, 1.3 Hz, H-4), 
7.63 (1H, dd, J = 2.8, 1.0 Hz, H-8), 7.25 (1H, dd, J = 7.3, 5.2 Hz, H-3), 6.96 (1H, dd, J 
= 3.8, 1.0 Hz, H-6), 6.48 (1H, dd, J = 3.8, 2.8 Hz, H-7); 
13
C NMR (50 MHz, DMSO- d6) 
δ: 176.5 (s), 156.2 (d), 152.2 (s), 132.8 (d), 131.7 (s), 123.2 (s), 121.4 (d), 120.6 (d), 
117.3 (d), 115.3 (d). Anal. Calculated for C10H6N2O (MW: 170.17): C, 70.58; H, 3.55; 
N, 16.46%. Found: C, 70.36; H, 3.66; N, 16.35%. 
 
 
3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-one (16i): 
 
Yield: 61%, yellow solid; mp: 161.2-161.5°C; IR: 1700 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 8.55 (1H, d, J = 2.2 Hz, H-2), 8.17 (1H, d, J = 2.2 Hz, H-4), 7.66 (1H, dd, 
J = 2.6, 0.7 Hz, H-8), 7.01 (1H, dd, J = 3.7, 0.7 Hz, H-6), 6.51 (1H, dd, J = 3.7, 2.6 Hz, 
H-7); 
13
C NMR (50 MHz, DMSO- d6) δ: 175.0 (s), 154.8 (s), 152.2 (d), 153.1 (d), 132.0 
(s), 125.1(s), 121.1 (d), 117.8 (d), 116.5 (s), 115.9 (d). Anal. Calculated for C10H5BrN2O 
(MW: 249.06 ): C, 48.22; H, 2.02; N, 11.25%. Found: C, 47.99; H, 2.42; N, 11.16%. 
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Synthesis of substituted -9H-pyrido[2,3-b]pyrrolizin-9-ylidenes (14b,d,e,h): 
To a solution of 9H-pyrido[2,3-b]pyrrolizin-9-one 14a (0.05 g, 0.29 mmol) in toluene (4 
mL) was added opportune heteroaryl carbohydrazide 27b,d,e,h (0.29 mmol). The 
resulting suspension was refluxed, using Dean-Stark apparatus, for 24-32 hours and 
then chilled overnight. The product was collected by filtration, washed with toluene and 
dried under vacuum to afford compound 14e. In the case of derivatives 14b,d,h the 
reaction mixture was quenched with a small amount of water, then extracted with DCM 
(3 x 10 mL), dried over anhydrous Na2SO4, filtered and evaporated in vacuo. It was 
purified by silica gel column cromatography eluting by DCM:MeOH, 97:3 (14b), DCM 
(14d) and DCM:Ethyl Acetate, 90:10 (14h) to give desired compound. 
N'-[9H-Pyrido[2,3-b]pyrrolizin-9-ylidene]pyridine-4-carbohydrazide (14b):  
 
Conditions: reflux for 24 hours.Yield: 49%, light brown powder; mp: 244.0-244.4 °C; 
IR: 3402 (NH), 1683 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 14.15 (1H, bs, NH), 
8.85 (2H, dd, J = 4.4, 1.8 Hz, H-2’ and H-6’), 8.38 (1H, dd, J = 5.0, 1.8 Hz, H-2), 7.88 
(2H, dd, J = 4.4, 1.8 Hz, H-3’ and H-5’), 7.57 (1H, dd, J = 7.9, 1.8 Hz, H-3), 7.38 (1H, 
dd, J = 7.9, 5.0 Hz, H-4), 7.10 (1H, d, J = 3.0 Hz, H-6), 6.89 (1H, d, J = 3.7 Hz, H-8), 
6.41 (1H, t, J = 3.7 Hz, H-7); 
13
C NMR (50 MHz, CDCl3) δ: 162.0 (s), 150.8 (d x 2), 
147.5 (s), 143.5 (d), 140.1 (s), 139.7 (s), 136.2 (s), 130.6 (s), 125.1 (d), 121.3 (d x 2), 
117.5 (d), 116.3 (d), 115.9 (d), 109.8 (d). Anal. Calculated for C16H11N5O (MW: 
289.29): C, 66.43; H, 3.83; N, 24.21%. Found: C, 66.21; H, 3.68; N, 24.36%. 
N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]furan-2-carbohydrazide (14d): 
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Conditions: reflux for 32 hours. Yield: 62%, yellow oil; IR: 3317 (NH), 1680 (CO) cm
-
1
; 
1
H NMR (200 MHz, CDCl3) δ: 13.95 (1H, bs, NH), 8.40 (1H, dd, J = 3.4, 0.8 Hz, H-
2), 7.63 (1H, d, J = 0.6 Hz, H-4), 7.55 (1H, dd, J = 8.0, 1.3 Hz, H-4’), 7.36 (2H, t, J = 
8.0 Hz, H-3’ and H-5’), 7.08 (1H, dd, J = 3.2, 0.6 Hz, H-3), 6.85 (1H, d, J = 3.1 Hz, H-
6), 6.60 (1H, d, J = 3.6 Hz, H-8), 6.39 (1H, t, J = 3.6 Hz, H-7); 
13
C NMR (50 MHz, 
CDCl3) δ: 155.2 (s), 147.4 (s), 147.1 (s), 145.0 (d), 143.5 (d), 138.6 (s), 135.9 (s), 130.9 
(s), 124.6 (d), 117.1 (d), 116.1 (d), 115.9 (d), 115.4 (d), 112.3 (d), 109.0 (d). Anal. 
Calculated for C15H10N4O2 (MW: 278.27 ): C, 64.74; H, 3.62; N, 20.13%. Found: C, 
64.89; H, 3.58; N, 20.07%. 
 
N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]thiophene-2-carbohydrazide (14e): 
 
Conditions: reflux for 24 hours. Yield: 50%, dark yellow powder; mp: 163.0-163.7°C; 
IR: 3428 (NH), 1656 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 13.93 (1H, bs, NH), 
8.50 (1H, d, J = 5.1, 1.2 Hz, H-2), 8.12 (1H, dd, J = 8.1, 1.2 Hz, H-4), 8.00 (1H, dd, J = 
5.1, 1.2 Hz, H-3), 7.90-7.84 (1H, m, H-4’), 7.64-7.58 (2H, m,  H-3’ and H-5’), 7.30 
(1H, t, J = 3.8 Hz, H-6), 6.75 (1H, dd, J = 3.6, 0.8 Hz, H-8), 6.44 (1H, t, J = 3.6 Hz, H-
7); 
13
C NMR (50 MHz, DMSO-d6) δ: 164.7 (s), 146.1 (s), 143.9 (d), 137.2 (s), 135.7 (s), 
132.8 (s), 129.6 (d), 129.0 (d), 128.2 (d), 125.8 (d), 125.3 (s), 119.1 (d), 117.7 (d), 115.4 
(d), 107.5 (d). Anal. Calculated for C15H10N4OS (MW: 294.33): C, 61.21; H, 3.42; N, 
19.04%. Found: C, 61.35; H, 3.28; N, 19.14%. 
 
N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]benzohydrazide (14h):  
 
Conditions: reflux for 27 hours. Yield: 56%, yellow powder; mp: 177.2-178.0°C; IR: 
3393 (NH), 1681 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 13.90 (1H, bs, NH), 
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8.50 (1H, dd, J = 4.8, 0.8 Hz, H-2), 8.11 (1H, dd, J = 8.2, 0.8 Hz, H-4), 7.98 (2H, dd, J 
= 6.2, 1.4 Hz, H-2’ and H-6’), 7.70-7.53 (5H, m, H-3’, H-4’, H-5’, H-3 and H-6), 6.74 
(1H, d, J = 3.3 Hz, H-8), 6.44 (1H, t, J = 3.1 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) 
δ: 162.3 (s), 146.2 (s), 143.9 (d), 138.3 (s), 135.7 (s), 133.2 (s), 132.6 (d), 129.7 (s), 
129.1 (d x 2), 127.2 (d), 125.7 (d x 2), 119.1 (d), 117.7 (d), 115.4 (d), 107.7 (d). Anal. 
Calculated for C17H12N4O (MW: 288.30): C, 70.82; H, 4.20; N, 19.43%. Found: C, 
70.75; H, 4.31; N, 19.29%. 
 
Synthesis of substituted -9H-pyrido[2,3-b]pyrrolizin-9-ylidenes (14c,f,g): 
To a solution of 9H-pyrido[2,3-b]pyrrolizin-9-one 14a (0.065 g, 0.38 mmol) in 
anhydrous ethanol (5 mL) was added opportune heteroaryl carbohydrazide 27c,f,g (0.38 
mmol). The resulting solution was heated to reflux for 24 hours and then chilled 
overnight. The product was collected by filtration, washed with cold ethanol and dried 
under vacuum to afford desired compound 14f-g, or purified by silica gel column 
cromatography using DCM:Ethyl Acetate, 75:25 as eluent to give products 14c. 
N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]pyridine-3-carbohydrazide (14c): 
 
Yield: 88%, yellow powder; mp: 182.5-182.7°C; IR: 3385 (NH), 1684 (CO) cm
-1
; 
1
H 
NMR (200 MHz, DMSO-d6) δ: 13.92 (1H, bs, NH), 9.13 (1H, s, H-2’), 8.85 (1H, d, J = 
4.1 Hz, H-6’), 8.49 (1H, dd, J = 5.0, 1.1 Hz, H-2), 8.32 (1H, d, J = 8.0 Hz, H-4), 8.11 
(1H, dd, J = 8.0, 1.2 Hz, H-3), 7.70-7.57 (3H, m, H-4’, H-5’ and H-6), 6.77 (1H, d, J = 
3.2 Hz, H-8), 6.44 (1H, t, J = 3.1 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) δ: 161.0 (s), 
148.8 (d), 146.4 (s), 145.5 (s), 144.0 (d), 135.8 (s), 129.6 (s), 128.5 (s), 125.9 (d), 123.9 
(d), 119.2 (d), 118.0 (d), 117.9 (d), 115.5 (d), 115.3 (d), 108.2 (d). Anal. Calculated for 
C16H11N5O (MW: 289.29): C, 66.43; H, 3.83; N, 24.21%. Found: C, 66.28; H, 3.76; N, 
24.11%. 
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4-Amino-N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]benzohydrazide (14f): 
 
 
Yield: 40%, yellow powder; mp: 276.1-277.0°C; IR: 3447 – 3337 (NH2), 3227 (NH), 
1662 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 13.73 (1H, bs, NH), 8.56 (1H, dd, J 
= 5.0, 1.0 Hz, H-2), 8.15 (1H, dd, J = 8.1, 1.0 Hz, H-4), 7.74 (2H, d, J = 8.6 Hz, H-2’ 
and H-6’), 7.64 (2H,  m, H-6 and H-8), 6.72 (3H, m, H-3’, H-5’ and H-3), 6.48 (1H, t, J 
= 3.4 Hz, H-7), 6.07 (2H, bs, NH2); 
13
C NMR (50 MHz, DMSO-d6) δ: 162.3 (s), 152.9 
(s), 146.2 (s), 143.9 (d), 136.5 (s), 135.4 (s), 130.1 (s), 129.1 (d), 125.3 (d), 118.9 (d), 
118.5 (s), 117.0 (d x 2), 115.3 (d), 113.1 (d x 2), 106.7 (d). Anal. Calculated for 
C17H13N5O (MW: 303.32): C, 67.32; H, 4.32; N, 23.09%. Found: C, 67.45; H, 4.15; N, 
23.31%. 
 
4-Hydroxy-N'-[9H-pyrido[2,3-b]pyrrolizin-9-ylidene]benzohydrazide (14g): 
 
Yield: 80%, light yellow solid; mp: 294.5-295.3 °C; IR: 3415 (NH), 3201 (OH), 1675 
(CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 13.78 (1H, bs, NH), 10.35 (1H, bs, OH), 
8.51 (1H, dd, J = 5.0, 1.3 Hz, H-2), 8.08 (1H, dd, J = 8.1, 1.3 Hz, H-3), 7.85 (2H, d, J = 
8.8 Hz, H-2’ and H-6’), 7.60 (2H,  m, H-4 and H-6), 6.95 (2H, d, J = 8.8 Hz, H-3’ and 
H-5’), 6.70 (1H, d, J = 3.7 Hz, H-8), 6.43 (1H, t, J = 3.7 Hz, H-7); 13C NMR (50 MHz, 
DMSO-d6) δ: 162.0 (s), 161.3 (s), 146.2 (s), 143.9 (d), 137.4 (s), 135.5 (s), 129.9 (s), 
129.4 (d), 125.5 (d x 2), 123.0 (s), 118.9 (d), 117.3 (d), 115.7 (d x 2), 115.3 (d), 107.2 
(d). Anal. Calculated for C17H12N4O2 (MW: 304.30): C, 67.10; H, 3.97; N, 18.41%. 
Found: C, 67.43; H, 3.85; N, 18.08%. 
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Synthesis of substituted -5H-pyrido[3,2-b]pyrrolizin-5-ylidenes (16b,d,e,h) : 
Method A: To a solution of 5H-pyrido[3,2-b]pyrrolizin-5-one 16a (0.06 g, 0.35 mmol) 
in a mixture of ethanol:toluene (1:3, 5 mL) was added isonicotinic hydrazide 27b  
(0.048 g, 0.35 mmol). The resulting solution was refluxed for 36 hours and then chilled 
overnight. The reaction mixture was quenched with a small amount of water, then 
extracted with ethyl acetate (3 x 10 mL), dried over anhydrous Na2SO4, filtered and 
evaporated in vacuo. It was purified by silica gel column cromatography eluting by 
DCM:MeOH, 9:1 to give desired compound 16b. Yield: 25%.  
Method B: To a solution of 5H-pyrido[3,2-b]pyrrolizin-5-one 16a (0.06 g, 0.35 mmol) 
in toluene (4 mL) was added opportune heteroaryl carbohydrazide 27b,d,e,h (0.35 
mmol). The resulting suspension was refluxed, using Dean-Stark apparatus, for 24-30 
hours and then chilled overnight. The reaction mixture was quenched with a small 
amount of water, then extracted with ethyl acetate (3 x 10 mL), dried over anhydrous 
Na2SO4, filtered and evaporated in vacuo. It was purified by silica gel column 
cromatography eluting by Ethyl Acetate (16b), DCM:Ethyl Acetate, 9:1 (16d), 
DCM:Ethyl Acetate, 95:5 (16e) and DCM:Ethyl Acetate, 80:20 (16h) to give desired 
compound. Yield: 49-87%. 
 
N'-[5H-Pyrido[3,2-b]pyrrolizin-5-ylidene]pyridine-4-carbohydrazide (16b): 
 
Conditions: reflux for 24 hours. Yield: 51%, light brown powder; mp: 236.3-236.8 °C; 
IR: 3353 (NH), 1702 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 11.50 (1H, bs, NH), 
8.81 (2H, d, J = 5.4 Hz, H-2’ and H-6’), 8.40 (1H, dd, J = 5.1, 1.4 Hz, H-2), 8.13 (1H, 
dd, J = 7.4, 1.4 Hz, H-4), 7.88 (2H, d, J = 5.4 Hz, H-3’ and H-5’), 7.64 (1H, d, J = 2.6 
Hz, H-6), 7.30  (1H, dd, J = 7.4, 5.1 Hz, H-3), 7.08 (1H, d, J = 2.6 Hz, H-8), 6.57 (1H, t, 
J = 2.6 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) δ: 163.4 (s), 152.6 (s), 150.3 (d), 
149.5 (d), 142.9 (s), 140.4 (s), 131.1 (d), 126.4 (s), 123.6 (s), 121.9 (d), 120.6 (d x 2), 
116.4 (d x 2), 115.8 (d), 114.9 (d). Anal. Calculated for C16H11N5O (MW: 289.29): C, 
66.43; H, 3.83; N, 24.21%. Found: C, 66.03; H, 4.03; N, 24.09%. 
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N'-[5H-Pyrido[3,2-b]pyrrolizin-5-ylidene]furan-2-carbohydrazide (16d): 
 
Conditions: reflux for 30 hours. Yield: 87%, dark yellow powder; mp: 247.2-247.8°C; 
IR: 3327 (NH), 1685 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 9.71 (1H, bs, NH), 
8.31 (1H, dd, J = 5.2, 1.6 Hz, H-2), 8.22 (1H, d, J = 7.6 Hz, H-4), 7.63 (1H, d, J = 3.2 
Hz, H-3’), 7.48 (1H, dd, J = 3.4, 1.0 Hz, H-4’), 7.43 (1H, d, J = 1.2 Hz, H-5’), 7.14  
(1H, dd, J = 7.6, 5.2 Hz, H-3), 6.87 (1H, d, J = 3.6 Hz, H-6), 6.64 (1H, dd, J = 3.6, 1.8 
Hz, H-8), 6.57 (1H, dd, J = 3.6, 2.9 Hz, H-7); 
13
C NMR (50 MHz, CDCl3) δ: 154.3 (s), 
153.1 (s), 149.2 (d), 146.6 (d), 145.0 (s), 139.3 (s), 131.5 (d), 126.0 (s), 123.9 (s), 120.3 
(d), 117.5 (d), 116.4 (d), 116.3 (d), 112.9 (d), 111.8 (d). Anal. Calculated for 
C15H10N4O2 (MW: 278.27 ): C, 64.74; H, 3.62; N, 20.13%. Found: C, 64.59; H, 3.55; N, 
20.24%. 
N'-[5H-Pyrido[3,2-b]pyrrolizin-5-ylidene]thiophene-2-carbohydrazide (16e): 
 
Conditions: reflux for 24 hours. Yield: 49%, light yellow solid; mp: 231.7-232.2°C; IR: 
3232 (NH), 1708 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 8.96 (1H, bs, NH), 8.33 
(2H, dd, J = 5.2, 1.4 Hz, H-2 and H-8 ), 8.16 (1H, d, J = 7.4 Hz, H-4 ), 7.63 (1H, dd, J = 
7.4, 1.2 Hz, H-3), 7.49 (1H, d, J = 2.6 Hz, H-4’), 7.20-7.14 (m, 2H, H-3’ and H-5’), 
6.85 (1H, dd, J = 3.4, 1.4 Hz, H-6), 6.55 (1H, t, J = 3.4 Hz, H-7); 
13
C NMR (50 MHz, 
CDCl3) δ: 152.7 (s), 149.0 (d), 146.8 (d), 141.4 (d), 131.0 (s), 129.7 (d), 120.1 (s), 118.8 
(s), 116.5 (s), 116.2 (d), 112.9 (d), 112.4 (d), 111.6 (d), 105.5 (d), 103.6 (s). Anal. 
Calculated for C15H10N4OS (MW: 294.33): C, 61.21; H, 3.42; N, 19.04%. Found: C, 
60.91; H, 3.57; N, 19.19%. 
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N'-[5H-Pyrido[3,2-b]pyrrolizin-5-ylidene]benzohydrazide (16h): 
 
Conditions: reflux for 24 hours. Yield: 71%, light orange powder; mp: 239.6-240.2°C; 
IR: 3385 (NH), 1685 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 9.36 (1H, bs, NH), 
8.31 (1H, dd, J = 5.2, 1.6 Hz, H-2), 8.21 (1H, d, J = 7.1 Hz, H-4), 7.95 (2H, dd, J = 6.4, 
2.2 Hz, H-6 and H-8), 7.63-7.48 (4H, m, H-2’, H-3’, H-5’ and H-6’), 7.15 (1H, dd, J = 
7.5, 5.2 Hz, H-3), 6.72 (1H, s, H-4’), 6.55 (1H, t, J = 2.8 Hz, H-7); 13C NMR (50 MHz, 
CDCl3) δ: 163.8 (s), 153.1 (s), 149.1 (d), 132.9 (s), 132.5 (d), 131.4 (d), 129.0 (d), 127.5 
(d), 125.9 (s), 124.0 (s), 120.3 (d), 116.3 (d x 2), 116.2 (d), 115.7 (s), 111.6 (d x 2). 
Anal. Calculated for C17H12N4O (MW: 288.30): C, 70.82; H, 4.20; N, 19.43%. Found: 
C, 70.57; H, 4.35; N, 19.23%.  
 
 
 
 
Synthesis of substituted -5H-pyrido[3,2-b]pyrrolizin-5-ylidenes (16c,f,g): 
 
To a solution of 5H-pyrido[3,2-b]pyrrolizin-5-one 16a (0.07 g, 0.41 mmol) in 
anhydrous ethanol (6 mL) was added opportune heteroaryl carbohydrazide 27c,f,g (0.41 
mmol). The resulting solution was heated to reflux for 24 hours and then chilled 
overnight. The precipitate formed was filtered, washed with cold ethanol and dried 
under vacuum to give derivative 16g, or purified by silica gel column cromatography 
using DCM:MeOH, 99:1 as eluent to give products 16c,f.  
N'-[5H-Pyrido[3,2-b]pyrrolizin-5-ylidene]pyridine-3-carbohydrazide (16c): 
 
63 
 
Yield: 60%, dark yellow powder; mp: 202.5-203.2°C; IR: 3379 (NH), 1674 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 11.43 (1H, br s, NH), 9.11 (1H, s, H-2’), 8.80 (1H, 
dd, J = 5.2, 1.6 Hz, H-2), 8.37 (2H, dt, J = 5.2, 3.2 Hz, H-3 and H-7), 8.14-8.11 (1H, m, 
H-5’), 7.64-7.57 (2H, m, H-4’ and H-6’), 7.28 (1H, dd, J = 7.4, 5.2 Hz, H-4), 7.13 (1H, 
s, H-8), 6.57 (1H, t, J = 3.2 Hz, H-6); 
13
C NMR (50 MHz, DMSO-d6) δ: 163.4 (s), 159.4 
(s), 152.6 (s), 152.2 (d), 149.4 (d), 148.9 (d), 136.0 (d), 130.9 (d), 129.1 (s), 126.3 (s), 
123.7 (s), 123.6 (d), 120.5 (d), 116.4 (d), 116.2 (d), 114.7 (d). Anal.Calculated for 
C16H11N5O (MW: 289.29): C, 66.43; H, 3.83; N, 24.21%. Found: C, 66.65; H, 3.68; N, 
23.99%. 
 
4-Amino-N'-[5H-pyrido[3,2-b]pyrrolizin-5-ylidene]benzohydrazide (16f): 
 
Yield: 45%, yellow powder; mp: 265.4-266.3°C; IR:  3603 – 3559 (NH2), 3359 (NH), 
1725 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 10.67 (1H, bs, NH), 8.36 (1H, dd, J 
= 5.1, 1.4 Hz, H-2), 8.12 (1H, dd, J = 7.5, 1.4 Hz, H-3), 7.73 (2H, d, J = 8.6 Hz, H-2’ 
and H-6’), 7.60 (1H, d, J = 2.8 Hz, H-6), 7.30 (1H, dd, J = 7.5, 5.1 Hz, H-4), 6.99 (1H, 
d, J = 3.4 Hz, H-8), 6.65 (2H, d, J = 8.6 Hz, H-3’ and H-5’), 6.57 (1H, t, J = 3.4 Hz, H-
7), 5.91 (2H, bs, NH2); 
13
C NMR (50 MHz, DMSO-d6) δ: 164.1 (s), 152.7 (s), 152.3 (s), 
148.8 (d), 138.9 (s), 130.6 (d), 129.9 (d x 2), 126.5 (s), 123.9 (s), 120.4 (d), 118.9 (s), 
116.3 (d), 115.5 (d), 113.3 (d), 112.7 (d x 2). Anal. Calculated for C17H13N5O (MW: 
303.32): C, 67.32; H, 4.32; N, 23.09%. Found: C, 67.0; H, 4.15; N, 23.41%. 
 
4-Hydroxy-N'-[5H-pyrido[3,2-b]pyrrolizin-5-ylidene]benzohydrazide (16g): 
 
Yield: 85%, dark yellow powder; mp: 316.9-317.8°C; IR: 3390 (NH), 3198 (OH), 1675 
(CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 10.94 (1H, bs, NH), 10.24 (1H, bs, OH), 
8.38 (1H, dd, J = 5.2, 1.5 Hz, H-2), 8.13 (1H, dd, J = 7.6, 1.5 Hz, H-4 ), 7.87 (2H, d, J = 
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8.7 Hz, H-2’ and H-6’), 7.61 (1H, dd, J = 2.8,  0.8 Hz, H-8), 7.29  (1H, dd, J = 7.6, 5.2 
Hz, H-3), 7.01 (1H, d, J = 3.4 Hz, H-6), 6.90 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 6.57 
(1H, td, J = 3.4, 0.8 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) δ: 164.1 (s), 161.0 (s), 
152.4 (s), 149.06 (d), 140.1 (s), 130.8 (d), 130.2 (d x 2), 126.5 (s), 123.8 (s), 123.5 (s), 
120.5 (d), 116.3 (d), 115.7 (d), 115.1 (d x 2), 113.8 (d). Anal. Calculated for 
C17H12N4O2 (MW: 304.30 ): C, 67.10; H, 3.97; N, 18.41%. Found: C, 66.8; H, 3.67; N, 
18.81%. 
 
Synthesis of substituted -3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidenes 
(16j,l,m,p): 
 
To a solution of 3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-one 16i (0.06 g, 0.24 mmol) in 
toluene (4 mL) was added opportune heteroaryl carbohydrazide 27b,d,e,h (0.24 mmol). 
The resulting suspension was refluxed, using Dean-Stark apparatus, for 24-48 hours and 
then chilled overnight. The product was collected by filtration, washed with toluene and 
dried under vacuum to afford compound 16m. In the case of derivatives 16j,l,p the 
reaction mixture was quenched with a small amount of water, then extracted with ethyl 
acetate (3 x 10mL), dried over anhydrous Na2SO4, filtered and evaporated in vacuo. The 
crude was purified by silica gel column cromatography eluting by DCM:Ethyl Acetate, 
60:40 (16j), Ciclohexane:Ethyl Acetate, 80:20 (16l) and Petroleum Ether:Ethyl Acetate, 
80:20 (16p) to give desired compound. 
 
N'-[3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]pyridine-4-carbohydrazide 
(16j): 
 
 
Conditions: reflux for 24 hours. Yield: 40%, yellow powder; mp: 250.0-250.6°C; IR: 
3371 (NH), 1689 (CO)  cm
-1
; 
1
H NMR (200 MHz, DMSO- d6) δ: 11.58 (1H, bs, NH), 
8.82 (2H, d, J = 5.0 Hz, H-2’ and H-6’), 8.53 (1H, d, J = 1.8 Hz, H-8), 8.27 (1H, s, H-
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2), 7.88 (2H, d, J = 5.0 Hz, H-3’ and H-5’), 7.64 (1H, d, J = 2.8 Hz, H-6), 7.13 (1H, s, 
H-4), 6.61 (1H, t, J = 3.0 Hz, H-7); 
13
C NMR (50 MHz, DMSO- d6) δ: 165.1 (s), 151.3 
(s), 150.3 (d), 149.8 (s), 149.6 (d), 140.4 (s), 133.1 (d), 126.8 (s), 125.7 (s), 122.0 (d), 
121.5 (d), 116.9 (d x 2), 116.6 (d x 2), 115.5 (s). Anal. Calculated for C16H10BrN5O 
(MW:368.19): C, 52.19; H, 2.74; N, 19.02%. Found: C, 52.29; H, 3.04; N, 18.72%. 
 
N'-[3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]furan-2-carbohydrazide (16l): 
 
Conditions: reflux for 27 hours. Yield: 45%, dark yellow solid; mp: 250.1-250.7°C; IR: 
3372 (NH), 1681 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 9.71 (1H, bs, NH), 8.36 
(1H, s, H-2), 8.10 (1H, d, J = 3.6 Hz, H-6), 7.63 (1H, s, H-4), 7.48 (2H, dd, J = 2.8, 0.6 
Hz, H-3’ and H-5’), 6.88 (1H, d, J = 3.4 Hz, H-8), 6.66  (1H, dd, J = 3.6, 1.8 Hz, H-7), 
6.58 (1H, dd, J = 3.6, 2.8 Hz, H-4’); 13C NMR (50 MHz, CDCl3) δ: 154.2 (s), 153.1 (s), 
149.1 (d), 146.6 (s), 145.0 (d), 139.2 (s), 131.6 (d), 126.0 (s), 123.8 (s), 120.2 (d), 117.1 
(d), 116.4 (d), 116.3 (s), 112.9 (d), 111.8 (d). Anal. Calculated for C15H9BrN4O (MW: 
357.16): C, 50.44; H, 2.54; N, 15.69%. Found: C, 50.14; H, 2.69; N, 16.09%. 
N'-[3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]thiophene-2-carbohydrazide 
(16m): 
 
Conditions: reflux for 24 hours. The product was characterized only by 
1
H NMR 
spectra, for its poor solubility, the 
13
C spectra wasn’t performed. Yield: 74%, yellow 
powder; mp: 276.4-277.0°C; IR: 3210 (NH), 1638 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 11.26 (1H, bs, NH), 8.51 (1H, d, J = 2.1 Hz, H-2), 8.27 (1H, d, J = 2.1 
Hz, H-4), 8.12 (1H, dd, J = 3.4, 0.8 Hz, H-8), 8.03 (1H, dd, J = 5.0, 1.0 Hz, H-6), 7.63 
(1H, d, J = 2.8 Hz, H-3’), 7.32 (1H, s, H-5’), 7.25 (1H, dd, J = 5.0, 3.8 Hz, H-7), 6.59 
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(1H, t, J = 3.0 Hz, H-4’). Anal. Calculated for C15H9BrN4OS (MW: 373.23): C, 48.27; 
H, 2.43; N, 15.01%. Found: C, 48.67; H, 2.58; N, 15.16%. 
 
N'-[3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]benzohydrazide (16p): 
 
Conditions: reflux for 48 hours. Yield: 35%, dark yellow solid; mp: 227.6-227.9°C; IR: 
3221 (NH), 1656 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 9.32 (1H, bs, NH), 8.34 
(2H, m, H-2 and H-4), 8.21 (2H, d, J = 6.6 Hz, H-6 and H-8), 7.64-7.45 (4H, m, H-2’, 
H-3’, H-5’ and H-6’), 6.73 (1H, s, H-4’), 6.56 (1H, t, J = 6.6 Hz, H-7); 13C NMR (50 
MHz, CDCl3) δ: 159.7 (s), 151.5 (s), 150.5 (s), 149.6 (d), 147.0 (s), 133.9 (d), 132.6 (d), 
129.0 (d), 127.7 (d), 126.1 (s), 125.6 (s), 116.8 (d x 2), 116.4 (d), 116.1 (s), 111.8 (d x 
2). Anal. Calculated for C17H11BrN4O (MW: 367.20): C, 55.61; H, 3.02; N, 15.26%. 
Found: C,55.35; H, 3.15; N, 14.98%. 
 
 
Synthesis of substituted -3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidenes (16k,n,o): 
To a solution of 3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-one 16i (0.07 g, 0.28 mmol) in 
anhydrous ethanol  (6 mL) was added opportune heteroaryl carbohydrazide 27c,f,g 
(0.28 mmol). The resulting solution was heated to reflux for 24 hours and then chilled 
overnight. The precipitate formed was filtered, washed with cold ethanol and dried 
under vacuum to give derivatives 16k,o or purified by silica gel column cromatography 
using DCM:Ethyl Acetate, 70:30 as eluent to afford product 16n.  
 
N'-[3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]pyridine-3-carbohydrazide 
(16k): 
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Yield: 63%, yellow solid; mp: 227.5-228.2°C; IR: 3187 (NH), 1652 (CO) cm
-1
; 
1
H 
NMR (200 MHz, DMSO-d6) δ: 11.50 (1H, bs, NH), 9.11 (1H, s, H-2’), 8.80 (1H, dd, J 
= 4.6, 1.0 Hz, H-6), 8.53 (1H, d, J = 2.0 Hz, H-6’), 8.33 (1H, d, J = 8.0 Hz, H-8), 8.24 
(1H, s, H-2), 7.65 (1H, d, J = 2.2 Hz, H-4’), 7.57 (1H, m, H-5’), 7.16 (1H, s, H-4), 6.60 
(1H, t, J = 3.2 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) δ: 164.2 (s), 152.4 (d), 151.2 
(s), 149.5 (d), 149.0 (d), 135.2 (s), 132.0 (d), 129.1 (s), 126.7 (s), 125.8 (s), 123.6 (d), 
121.1 (s), 116.9 (d), 116.5 (d), 115.9 (d), 115.0 (d). Anal. Calculated for C16H10BrN5O 
(MW: 368.19): C, 52.19; H, 2.74; N, 19.02%. Found: C 51.89; H, 2.92; N, 19.17%. 
4-Amino-N'-[3-bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]benzohydrazide (16n): 
 
Yield: 52%, dark yellow powder; mp: 289.1-290.0°C; IR: 3446 - 3340 (NH2), 3219 
(NH), 1662 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 9.19 (1H, bs, NH), 8.27 (2H, m, 
H-2 and H-6), 8.04 (1H, s, H-4), 7.73 (2H, d, J = 8.4 Hz, H-2’ and H-6’), 7.38 (1H, d, J 
= 2.6 Hz, H-8), 6.68 (2H, d, J = 8.4 Hz, H-3’ and H-5’), 6.50 (1H, t, J = 3.2 Hz, H-7), 
4.09 (2H, bs, NH2); 
13
C NMR (50 MHz, CDCl3) δ: 162.0 (s), 150.8 (d x 2), 147.5 (s), 
143.4 (d), 140.1 (s), 139.7 (s), 136.2 (s), 131.4 (s), 130.7 (s), 125.0 (s), 121.3 (d x 2), 
117.6 (d), 116.3 (d), 116.0 (d), 109.9 (d). Anal. Calculated for C17H12BrN5O (MW: 
382.21): C, 53.42; H, 3.16; N, 18.32%. Found: C 53.35; H, 3.23; N, 18.02%. 
 
N'-[3-Bromo-5H-pyrido[3,2-b]pyrrolizin-5-ylidene]-4-hydroxybenzohydrazide 
(16o): 
 
Yield: 93%, yellow powder; mp: 288.6-289.1°C; IR: 3586 (NH), 3324 (OH), 1672 (CO) 
cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 11.03 (1H, bs, NH), 10.26 (1H, bs, OH), 8.51 
(1H, d, J = 2.1 Hz, H-2), 8.26 (1H, d, J = 2.1 Hz, H-4), 7.87 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 7.64 (1H, d, J = 3.0 Hz, H-8), 7.04 (1H, d, J = 3.5 Hz, H-6), 6.93 (2H, d, J = 
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8.7 Hz, H-3’ and H-5’), 6.60 (1H, t, J = 3.5 Hz, H-7); 13C NMR (50 MHz, DMSO-d6) δ: 
164.2 (s), 161.0 (s), 151.1 (s), 149.2 (d), 138.6 (s), 132.8 (d), 130.4 (d x 2), 126.9 (s), 
125.9 (s), 123.4 (s), 116.8 (d), 116.0 (d), 115.4 (s), 115.1 (d x 2), 114.2 (d). Anal. 
Calculated for C17H11BrN4O2 (MW: 383.20): C, 53.28; H, 2.89; N, 14.62%. Found: C 
53.40; H, 3.01; N, 14.87%. 
 
Aza-indoles’ series: 
Synthesis of ethyl cyano(3-nitropyridin-yl)acetates (30a,b-31a): 
To a stirring solution of t-BuOK (1.7 g, 15.2 mmol) in t-BuOH (20 mL) ethyl 
cyanoacetate (1.8 mL, 16.56 mmol) was added. After 10 minutes, a solution of 
appropriate chloro-3-nitropyridine 28a-b, 29a (7.6 mmol)  in t-BuOH was added and 
the resulting mixture heated to reflux for 12 hours. Upon cooling to room temperature, 
the reaction mixture was concentrated under reduced pressure and washed with 1M 
HCl, filtered and recrystallized from ethanol to give desired compound.  
 
Ethyl cyano(3-nitropyridin-2-yl)acetate (30a)
44
 : 
 
Yield: 80%, orange solid; mp: 136.4-136.9°C; IR: 3556 (OH), 2190 (CN) cm
-1
; 
1
H 
NMR (200 MHz, DMSO-d6) δ: 14.49 (1H, bs, OH), 8.46 (1H, d, J = 8.0 Hz, H-6), 8.36 
(1H, d, J = 4.0 Hz, H-4),  7.05 (1H, t, J = 8.0 Hz, H-5 ), 4.23 (2H, q, J = 7.0 Hz, CH2), 
1.26 (3H, t , J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO-d6) δ: 168.3 (s), 146.1 (s), 
142.0 (d), 138.8 (d), 134.5 (s), 125.9 (s), 116.2 (s), 112.2 (d), 60.2 (t), 14.3 (q).  Anal. 
Calculated for C10H9N3O4 (MW: 235.20): C, 51.07; H, 3.86; N, 17.87%. Found: C, 
51.27, H, 3.69; N, 17.78%. 
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Ethyl cyano(6-methoxy-3-nitropyridin-2-yl)acetate (30b): 
 
Yield: 75%, light yellow solid; mp: 72.9-73.4°C; IR: 2224 (CN), 1720 (CO) cm
-1
; 
1
H 
NMR (200 MHz, CDCl3) δ: 8.46 (1H, d,  J = 9.1 Hz, H-4), 6.93 (1H, d,  J = 9.1 Hz, H-
5), 5.86 (1H, s, CH),  4.34 (2H, q, J = 7.1 Hz, CH2),  4.12 (3H, s, OCH3), 1.35 (3H, t,  J 
= 7.1 Hz, CH3); 
13
C NMR  (50 MHz, CDCl3) δ: 165.5 (s), 162.9 (s), 145.0 (s), 138.4 (s), 
136.8 (d), 113.3 (s), 112.7 (d), 63.9 (t), 55.5 (q), 45.6 (d), 13.9 (q). Anal. Calculated for 
C11H11N3O5 (MW: 265.22): C, 49.81; H, 4.18; N, 15.84%. Found: C, 50.01, H, 4.29; N, 
15.99%. 
 
Ethyl cyano(3-nitropyridin-4-yl)acetate (31a)
45
: 
 
 
Quantitative yield, yellow powder; mp: 177.8-178.8°C; IR: 3558 (OH), 2200 (CN) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 13.39 (1H, bs, OH), 8.70 (1H, s, H-2), 7.87-7.90 
(2H, m, H-5 and H-6), 4.07 (2H, q,  J = 7.0 Hz, CH2), 1.18 (3H, t,  J = 7.0 Hz, CH3); 
13
C 
NMR (50 MHz, DMSO-d6) δ: 164.8 (s), 145.5 (s), 137.9 (d), 136.6 (s), 135.7 (d), 119.0 
(s), 117.6 (d), 70.7 (s), 59.5 (t), 14.4 (q). Anal. Calculated for C10H9N3O4 (MW: 
235.20): C, 51.07; H, 3.86; N, 17.87%. Found: C, 51.24, H, 3.72; N, 17.76%. 
 
 
 
Synthesis of ethyl 2-amino-1H-pyrrolo[3,2-b]pyridine-3-carboxylates, ethyl 2-
amino-1H-pyrrolo[2,3-c]pyridine-3-carboxylate (32a-b, 33a):  
 
To a stirring solution of opportune ethyl cyano(3-nitropyridin-yl)acetate 30a-b, 31a 
(2.12 mmol) in acetic acid (4 mL) iron powder (0.75 g, 13.44 mmol) was added. The 
resulting dark solution was stirred at room temperature for 4-5 hours. The reaction 
mixture, added an aqueous saturated Na2CO3 solution until pH 9-10, was extracted with 
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ethyl acetate (3 x 15 mL), dried over anhydrous Na2SO4, filtered and evaporated to give 
desired compound. 
 
Ethyl 2-amino-1H-pyrrolo[3,2-b]pyridine-3-carboxylate (32a)
44
: 
 
Conditions: room temperature for 5 hours. Yield: 85%, light green solid; mp: 110.8-
111.5°C; IR: 3557 - 3534 (NH2), 3279 (NH), 1720 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO-d6) δ: 10.85 (1H, bs, NH), 8.09 (1H, dd, J = 5.0, 1.4 Hz, H-5), 7.35 (1H, dd, J = 
7.8, 1.4 Hz, H-7), 7.06 (2H, bs, NH2), 6.85 (1H, dd, J = 7.8, 5.0 Hz, H-6), 4.25 (2H, q, J 
= 7.0 Hz, CH2), 1.28 (3H, t,  J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO-d6) δ: 165.7 
(s), 156.1 (s), 145.5 (s), 141.3 (d), 127.1 (s), 115.9 (d), 114.8 (d), 84.5 (s), 58.6 (t), 15.3 
(q). Anal. Calculated for C10H11N3O2 (MW: 205.21): C, 58.53; H, 5.40; N, 20.48%. 
Found: C, 58.64; H, 5.20; N, 20.22%. 
 
Ethyl 2-amino-5-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxylate (32b):  
 
 
Conditions: room temperature for 4 hours. Yield: 79%, brown solid; mp: 229.2-
230.0°C; IR: 3483 - 3395 (NH2), 3267 (NH), 1651 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 10.54 (1H, bs, NH), 7.32 (1H, d, J = 8.4 Hz, H-7), 6.84 (2H, bs, NH2), 
6.25 (1H, d, J = 8.4 Hz, H-6), 4.20 (2H, q, J = 6.9 Hz, CH2), 3.84 (3H, s, OCH3), 1.35 
(3H, t, J = 6.9 Hz, CH3); 
13
C NMR (50 MHz, DMSO- d6) δ: 165.3 (s), 159.0 (s), 154. 4 
(s), 142.2 (s), 120.9 (s), 119.1 (d), 99.7 (d), 84.7 (s), 57.9 (t), 52.2 (q), 14.5 (q). Anal.  
Calculated for C11H13N3O3 (MW: 235.24): C, 56.16; H, 5.57; N, 17.86%. Found: C, 
56.34; H, 5.69; N, 17.98%. 
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Ethyl 2-amino-1H-pyrrolo[2,3-c]pyridine-3-carboxylate (33a)
45
:  
 
 
Conditions: room temperature for 5 hours. Yield: 88%, light orange solid; mp: 151.6-
152.6°C; IR: 3429 - 3396 (NH2), 3315 (NH), 1678 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO-d6) δ: 10.35 (1H, bs, NH), 8.32 (1H, s, H-7), 8.03 (1H, d, J = 2.0 Hz, H-5), 7.42 
(1H, d, J = 2.2 Hz, H-4), 7.21 (2H, bs, NH2), 4.24 (2H, q, J = 7.0 Hz, CH2), 1.34 (3H, t, 
J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO-d6) δ: 172.2 (s), 165.2 (s), 139.1 (d), 
133.3 (s), 129.4 (s), 129.3 (d), 112.4 (d), 84.2 (s), 58.5 (t), 14.6 (q). Anal. Calculated for 
C10H11N3O2 (MW: 205.21): C, 58.53; H, 5.40; N, 20.48%. Found: C, 58.60; H, 5.24; N, 
20.25%. 
 
Synthesis of ethyl 5-methoxy-2-(1H-pyrrol-1-yl)-1H-pyrrolo[3,2-b]pyridine-3-
carboxylate (34b): 
 
To a solution of 2,5-dimethoxytetrahydrofuran  (0.14 mL, 1.10 mmol)  in anhydrous 
1,4-dioxane (13 mL), was added 4-chloropyridine hydrochloride (0.16 g, 1.10 mmol) 
and the reaction mixture was stirred at room temperature for 15 minutes. Derivate 32b  
(0.26 g,1.10 mmol) was added and the reaction mixture was heated to reflux for 18 
hours. Upon cooling a precipitate formed, that was filtered and purified by silica gel 
column cromatography (DCM) to give desired compound 34b. Yield: 65%, brown 
solid; mp: 195.5-196.2°C; IR: 3267 (NH), 1704 (CO) cm
-1
; 
1
H NMR (200 MHz, 
DMSO- d6) δ: 12.45 (1H, bs, NH), 7.68 (1H, d, J = 8.5 Hz, H-7), 7.27 (2H, s, H-2’ and 
H-5’),  6.65 (1H, d, J = 8.5 Hz, H-6), 6.31 (2H, s, H-3’ and H-4’), 4.20 (2H, q, J = 6.3 
Hz, CH2), 3.92 (3H, s, OCH3), 1.24 (3H, t, J = 6.3 Hz, CH3); 
13
C NMR (50 MHz, 
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DMSO- d6) δ: 162.7 (s), 160.0 (s), 140.3 (s), 140.0 (s), 122.7 (d), 122.5 (d x 2), 121.5 
(s), 109.8 (d x 2), 105.8 (d), 99.6 (s), 59.1 (t), 52.6 (q), 14.1 (q). Anal. Calculated for 
C15H15N3O3 (MW: 285.30): C, 63.15; H, 5.30; N, 14.73%. Found: C, 63.06; H, 5.16; N, 
14.88%. 
 
Synthesis of 2-diazo-3-ethoxycarbonyl-pyrrolopyridines (40-41)a: 
To a solution of opportune derivate (32-33)a  (0.5 g, 2.44 mmol) in acetic acid  (4.6 
mL) at 0°C, under N2 atmosphere, a solution of sodium nitrite (NaNO2)  (0.19 g, 2.75 
mmol)  in a small amount of water was slowly added. The mixture was stirred at 0°C 
for 8 hours. Upon neutralizing with 15% Na2CO3 solution, the reaction mixture was 
extracted with DCM (3 x 15 mL) dried over anhydrous Na2SO4, filtered and evaporated 
to give desired compound. 
2-Diazo-3-ethoxycarbonyl-pyrrolo[3,2-b]pyridine (40a)
44
: 
 
Yield: 90%, brown solid; mp: 162.0°C dec.; IR: 2198 (N2
+
), 1714 (CO) cm
-1
; 
1
H NMR 
(200 MHz, DMSO-d6) δ: 6.99-8.72 (3H, m), 4.35 (2H, q,  J = 7.0 Hz, CH2), 1.34 (3H, t, 
J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO-d6) δ: 162.0 (s), 150.9 (d), 143.1 (s), 
140.5 (d), 131.1 (s), 129.9 (s), 114.8 (d), 114.6 (s), 59.1 (t), 14.6 (q). Anal.Calculated 
for C10H8N4O2 (MW: 216.20): C, 55.55; H, 3.73; N, 25.91%. Found: C, 55.24; H, 3.96; 
N, 25.72%. 
2-Diazo-3-ethoxycarbonyl-pyrrolo[2,3-c]pyridine (41a)
45
: 
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Yield: 90%, red/orange solid; mp: 168.0°C dec.; IR: 2191 (N2
+
), 1709 (CO) cm
-1
; 
1
H 
NMR (200 MHz, DMSO-d6) δ: 9.06 (1H, s, H-7), 7.75-8.59 (2H, m, H-4 and H-5), 4.24 
(2H, q, J = 7.0 Hz, CH2), 1.38 (3H, t, J = 7.0 Hz, CH3); 
13
C NMR (50 MHz, DMSO-d6) 
δ: 161.2 (s), 146.3 (d), 144.3 (s), 141.1 (d), 131.1 (s), 129.9 (s), 115.0 (d), 114.4 (s), 
60.9 (t), 14.1 (q). Anal.Calculated for C10H8N4O2 (MW: 216.20): C, 55.55; H, 3.73; N, 
25.91%. Found: C, 55.17; H, 3.92; N, 25.70%. 
 
 
Synthesis of  3-(ethoxycarbonyl)-1H-pyrrolopyridine-2-diazonium tetrafluoborates 
 (42-43)a:  
 
To a solution of opportune diazo (40-41)a (0.2 g, 0.92 mmol) in anhydrous diethyl ether 
(4 mL) at -10°C, under N2 atmosphere, a solution of tetrafluoroboric acid (0.15 mL, 
0.92 mmol) in a small amount of diethyl ether was slowly added. The mixture was 
warmed to 0°C and stirred overnight. A yellow solid was formed, filtered off,  washed 
with water and dried under vacuum. The crude was taken up onto the next step that 
unfortunately didn’t work. 
 
 
 
Synthesis of  (2-amino-1H-pyrrolo[2,3-c]pyridin-3-yl)(pyrrolidin-1-yl)methanone 
(46a):  
 
To a stirred solution of 1-(cianoacetyl)-pyrrolidine 44 (0.35 g, 2.5 mmol) in anhydrous 
DMF (3 mL) was slowly added NaH (60% dispersion in mineral oil, 0.07 g, 2.75 
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mmol). After 10 minutes, 4-chloro-3-nitropyridine 29a (0.4 g, 2.5 mmol) was added and 
the reaction mixture became deep purple. After 1 hour at room temperature, 1.0 N HCl 
(5.0 mmol) was added, following FeCl3 (1.22 g, 7.5 mmol) and Zn dust (1.6 g, 25 
mmol). The reaction mixture was heated to 100°C for 1 hour. Upon cooling, the crude, 
added of water (25 mL), was extracted with ethyl acetate (3 x 30 mL) and washed by an 
aqueous saturated NaHCO3 solution (20 mL) and brine (20 mL). The organic layer was 
dried over anhydrous Na2SO4, filtered and evaporated in vacuo. The crude was purified 
by silica gel column cromatography using Petroleum Ether:Ethyl Acetate, 70:30 as 
eluent to give desired compound 46a. Yield: 30%, uncolorless oil; IR: 3463 - 3388 
(NH2), 3192 (NH), 1615 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 8.12 (1H, s, H-7), 
7.87 (1H, d, J = 5.2 Hz, H-5), 7.16 (1H, d, J = 5.2 Hz, H-4), 4.33 (2H, bs, NH2), 1.63-
1.50 (2H, m, CH2), 1.29-1.14 (4H, m, CH2 x 2), 0.90-0.83 (2H, m, CH2); 
13
C NMR (50 
MHz, CDCl3) δ: 171.0 (s), 140.6 (s), 139.2 (d), 137.9 (s), 135.5 (d), 127.6 (s), 124.2 (d), 
82.4 (s), 60.7 (t), 41.3 (t), 28.6 (t), 17.3 (t). Anal.Calculated for C10H8N4O2 (MW: 
230.27): C, 62.59; H, 6.13; N, 24.33%. Found: C, 62.74; H, 6.33; N, 24.47%. 
 
Synthesis of pyrrolidin-1-yl[2-(1H-pyrrol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-
yl]methanone (37a): 
 
To a solution of 2,5-dimethoxytetrahydrofuran (0.14 mL, 1.09 mmol) in dry 1,4-
dioxane (13.0 mL), was added 4-chloropyridine hydrochloride (0.16 g, 1.09 mmol) and 
the reaction mixture was stirred at room temperature for 15 min. (2-amino-1H-
pyrrolo[2,3-c]pyridin-3-yl)(pyrrolidin-1-yl)methanone 46a (0.25 g, 1.09 mmol) was 
added and the reaction mixture was heated to reflux for 90 minutes. Upon cooling, a 
precipitate formed, that was filtered. The solid was discarded, while the mother liquor 
containing the title compound was evaporated in vacuo and the residue was purified by 
silica gel column cromatography, using Petroleum Ether:Ethyl Acetate, 85:15 to give 
desired derivative 37a. Yield: 55%, light yellow oil; IR: 3417 (NH), 1646 (CO) cm
-1
; 
1
H 
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NMR (200 MHz, CDCl3) δ: 8.57 (1H, s, H-7), 8.44 (1H, d, J = 5.2 Hz, H-5), 7.44 (1H, 
d, J = 5.2 Hz, H-4), 6.91 (2H, t, J = 2.2 Hz, H-2’ and H-5’), 6.37 (2H, t, J = 2.2 Hz, H-
3’ and H-4’), 1.5-1.14 (4H, m, CH2 x 2), 1.03-0.85 (4H, m, CH2 x 2); 
13
C NMR (50 
MHz, CDCl3) δ: 155.6 (s), 148.9 (d), 148.1 (d), 147.9 (s), 138.9 (s), 135.5 (s), 125.3 (d), 
122.0 (d x 2), 110.4 (d x 2), 109.7 (s), 59.7 (t), 41.3 (t), 28.7 (t), 17.6 (t). 
Anal.Calculated for C10H8N4O2 (MW: 280.32): C, 68.55; H, 5.75; N, 19.99%. Found: C, 
68.78; H, 5.55; N, 20.09%. 
 
BIOLOGY 
 
Drugs Preparation 
To obtain stock solutions of compounds 14a-i, 16a-p, each compound was initially 
dissolved in DMSO in order to obtain 50mM solution, stored at +4°C, and diluted in 
complete culture medium immediately before use at the appropriate concentration. 
 
Viability assay in vitro 
Tripentone analogues, prepared as described above, were dissolved in dimethyl 
sulfoxide (DMSO) (all reagents and chemicals were from Sigma Chemical Co (St. 
Louis, MO), unless indicated) and then diluted in culture medium to have a DMSO 
concentration not exceeding 0.1%. HCT-116 and Caco-2 cell lines were purchased from 
American Type Culture Collection, Rockville, MD, USA and DMEM supplemented 
with 10% fetal, 10% fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin 
(100 g/mL) and gentamicin (5 μg/mL). Cells were maintained in log phase by seeding 
twice a week at a density of 3 x 10
8 
cells/L in humidified 5% CO2 atmosphere, at 37 °C. 
In all experiments, HCT-116 and MCF-7 cells were made quiescent through overnight 
incubation before treatment with tested compounds or vehicle alone (control cells). 
No differences were found between cells treated with DMSO 0.1% and untreated cells 
in terms of cell number and viability. Cytotoxic activity of the tripentone derivatives 
14a-i and 14a-p was determined by the colorimetric assay based on the reduction of 3-
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(4,5-dimethyl-2-thiazolyl)bromide-2,5-diphenyl-2H-tetrazolium (MTT) to purple 
formazan by mitochondrial dehydrogenases. Briefly, HCT-116 and MCF-7 lines cells 
were seeded at 2 × 10
4
 cells/well in 96-well plates containing 200 μL RPMI. When 
appropriated, monolayer cultures were treated for 24 h with various concentrations (5-
100 M) of the drugs. Then cells were washed with fresh medium and 50 μL FBS-free 
medium containing 5 mg/mL MTT added. Cells were incubated 2 h at 37 °C, then 
medium was discarded by centrifugation, formazan blue formed in the cells dissolved in 
DMSO, and absorbance measured at 570 nm in a microplate reader (Bio-RAD, 
Hercules, CA). Formazan of control cells was taken as 100% viability. GI50 was 
calculated by the curve of percent viability versus concentration. Each experiment was 
repeated at least three times in triplicate.  
 
Cell cycle analysis 
Cell cycle stage was analyzed by flow cytometry. HCT-116 cells (5.0 x 10
4 
cells/cm
2
) 
were seeded in triplicate in 24-wells culture plates. After an overnight incubation, the 
cells were washed with fresh medium and incubated with compounds 16e and 16j in 
RPMI for 24 h. Then cells were harvested by trypsinization. Aliquots of 1x10
6
 cells 
were washed with PBS and incubated in the dark in a PBS solution containing 20 μg/ml 
propidium iodide (PI) and 200μg/ml RNase, for 30 min, at room temperature. Then 
samples of at least 1.0 x 10
4 
cells were subjected to fluorescence-activated cell sorting 
(FACS) analysis by Epics XL™ flow cytometer using Expo32 software (Beckman 
Coulter, Fullerton, CA). 
 
Measurement of phosphatidylserine (PS) exposure 
The apoptosis-induced PS externalization to the cell surface was measured by flow 
cytometry by double staining with Annexin V-Fluorescein isothiocyanate (Annexin V-
FITC)/propidium iodide (PI). Annexin V binding to phosphatidylserine is used to 
identify the earliest stage of apoptosis. PI, which does not enter cells with intact 
membranes, is used to distinguish between early apoptotic cells (Annexin V-FITC 
positive and PI negative), late apoptotic cells (Annexin V-FITC/PI-double positive) or 
77 
 
necrotic cells (annexin V-FITC negative and PI positive).  After 24 h treatment, HCT-
116 cells were harvested by trypsinization and adjusted at 1.0 x 10
6
 cells/mL with 
combining buffer according to the manufacturer instructions (eBioscience, San Diego, 
CA). One hundred μL of cell suspensions were added to a new tube, and incubated with 
Annexin V-FITC and PI solution at room temperature in the dark for 15 min. Then 
samples of at least 1.0 x 10
4 
cells were subjected to FACS analysis using appropriate 2-
bidimensional gating method. 
 
Statistics 
Results are given as means and their standard deviations. Three independent 
observations were carried out for each experiment, replicated three times. Statistical 
comparisons were made using a one-way ANOVA, followed by Bonferroni’s test. 
P<0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
REFERENCES 
 
1. Hadfield J-A, Ducki S, Hirst N, McGown A T, Progr. Cell Cycle Res., 2003, 5, 
309  
2. Kamal A, Nagaseshadri B, Lakshma Nayak V, Srinivasulu V, Sathish M, 
Sopanrao Kapure J, Suresh Reddy C, Bioorg. Chem., 2015, 63, 72  
3. Guenard D, Gueritte-Voegelein F, Lavelle F, Curr. Pharm. Design, 1995, 1, 95  
4. Brossi A, Yeh H J C, Med. Res. Rev., 1988, 8, 77 
5. Lavielle G, Hautefaye P, Schaeffer C, Boutin J A, Cudennec C A, Pierre A, J. 
Med. Chem., 1991, 34,  1998 
6. Hadfield J A, McGown A T, Synth. Commun., 1998, 28, 1421  
7. Swindell C S, Krauss N E, Horwitz S B, Ringel I, J. Med. Chem., 1991, 34, 
1176 
8. Li Q, Ham H L, Rosemberg S H,  Annual Rep. Med. Chem., 1999, 34, 139 
9. Ganugapati J, Mukundan M, Mandava A, Jaikumar Ahuja S, IJPSR, 2015, 6, 
2841 
10. Pettit G R, Singh S B, Hamel E, Lin C M, Alberts D S, Garcia-Kendall D, 
Experientia, 1989, 45, 209 
11. Lin C M, Singh S B, Chu P S, Dempcy R O, Schmidt J M, Pettit G R, Hamel E, 
Mol. Pharmacol., 1988, 34, 200 
12. Cretu E, Trifan A, Vasincu Al, Miron A, Rev. Med. Chir. Soc. Med. Nat., Iasi, 
2012, 116, 1223 
13. Rochais C, Dallemagne P, Rault S, Anti-Cancer Agents Med. Chem., 2009, 9, 
369  
14. Lancelot J C, Letois B, Rault S, Robba M, Rogosca M, J. Heterocycl. Chem., 
1994, 31, 501 
15. Lisowski V, Enguehard C, Lancelot J C, Caignard D H, Lambel S, Leonce S, 
Pierre A, Atassi G, Renard P, Rault S, Bioorg. Med. Chem. Lett., 2001, 11, 2205 
16. Lisowski V, Leonce S, Kraus-Berthier L, Oliviera Santos J S,  Pierre A, Atassi 
G, Caignard D H, Renard P, Rault S, J. Med. Chem., 2004, 47, 1448 
17. Rochais C, Crestell T, Perri V, Jouanne, M; Lesnard A,  Rault S, Dallemagne P, 
Cancer Lett., 2013, 331, 92 
79 
 
18. Diana P, Stagno A, Barraja P, Montalbano A, Carbone A, Parrino B, 
Cirrincione G, Tetrahedron, 2011, 67, 3374 
19. Rochais C, Lisowski V, Dallemagne P, Rault S, Bioorg. Med. Chem., 2006, 14, 
8162  
20. Rochais C, Vu Duc N, Lescot E, Bureau R, Meijer L, Dallemagne P, Rault S, 
Eur. J. Med. Chem., 2009, 44, 708  
21. Grande F, Aiello F, De Grazia O, Brizzi A, Garofalo A, Neamati N, Bioorg. 
Med. Chem., 2007, 15, 288 
22. Grande F, Yamada R, Cao X,  Aiello F, Garofalo A, Neamati N, Expert Opin. 
Investig. Drugs, 2009, 18, 555  
23. Lobert S, Vulevic B, Correia J J, Biochemistry, 1996, 35, 6806 
24. Jordan M A, Curr. Med. Chem. Anticancer Agents, 2002, 2, 1 
25. Uppuluri S, Knipling L, Sackett D L, Wolff J, Proc. Natl. Acad. Sci. USA, 1993, 
90, 11598 
26. Nogales E, Wolf S G, Khan I A, Luduena R F, Downing K H, Nature, 1995, 
375, 424 
27. Wall M E, Wani M C, Cancer Res., 1995, 55, 753 
28. Yvon A-M C, Wadsworth P, Jordan M A, Mol. Biol. Cell., 1999, 10, 947 
29. Amos L A, Löwe J, Chem. Biol., 1999, 6, R65 
30. Magnani M, Maccari G, Andreu J M, Diaz J F, Botta M, FEBS J., 2009, 276, 
2701 
31. Bollag D M, McQueney P A, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, 
Lazarides E, Woods C M, Cancer Res., 1995, 55, 2325 
32. Nettles J H, Li H, Cornett B, Krahn J M, Snyder J P, Downing K H., Science, 
2004, 305, 866 
33. Mooberry S L, Tien G, Hernandez A H, Plubrukarn A, Davidson B S, Cancer 
Res., 1999, 59, 653 
34. Mulzer J, Ohler E, Chem. Rev., 2003, 103, 3753 
35. Pryor D E, O’Brate A, Bilcer G, Dı´az J F, Wang Y, Wang Y, Kabaki M, Jung 
M K, Andreu J M, Ghosh A K, Giannakakou P, Hamel E, Biochemistry, 2002, 
41, 9109  
80 
 
36. Pineda O, Farras J, Maccari L, Manetti F, Botta M, Vilarasa J, Bioorg. Med. 
Chem. Lett., 2004, 14, 4825 
37. Schlieper D, Oliva M A, Andreu J M, Löwe J, PNAS, 2005, 102, 9170 
38. Ravelli R B, Gigant B, Curmi P A, Jourdain I, Lachkar S,  Sobel A, Knossow M, 
Nature, 2004, 428 (6979), 198 
39. Prota A E, Danel F, Bachmann F, Bargsten K, Buey R M, Pohlmann J, Reinelt 
S, Lane H, Steinmetz M O, J. Mol. Biol., 2014, 426 (8), 1848 
40. Gigant B, Wang C, Ravelli R B, Roussi F, Steinmetz M O, Curmi P A, Sobel A, 
Knossow M, Nature Lett., 2005, 435 (7041), 519 
41. Prota A E, Bargsten K, Northcote P T, Marsh M, Altmann K H, Miller J H, Diaz 
J F, Steinmetz M O, Angewandte Chemie, 2014, 53 (6), 1621 
42. Glide, version 5.9, Schrödinger, LLC, New York, NY, 2013 
43. Blum C A, Chenard B L, Martinez I, Zheng X, PCT Int. Appl. 2009, WO 
2009/121036 A2 
44.  Diana P, Stagno A, Barraja P, Carbone A, Montalbano A, Martorana A, Dattolo 
G, Cirrincione G, Arkivoc, 2009, viii, 177 
45. Diana P, Stagno A, Barraja P, Carbone A, Montalbano A, Martorana A, Dattolo 
G, Cirrincione G, Arkivoc, 2009, x, 1 
46. Wang K, Herdtweck E, Dömling A, Acs Comb. Sci., 2011, 13, 140 
47. Van Meerloo J,  Kaspers J G,  Cloos J, Methods Mol. Biol., 2011, 731, 237 
48. Ladurèe D, Robba M, Heterocycles, 1984, 22, 303 
 
 
 
 
 
 
 
81 
 
SYNTHESIS OF INTRACELLULAR ANTAGONISTS FOR CC 
CHEMOKINE RECEPTORS CCR1 AND CCR2 
 
Leiden Academic Centre for Drug Research (LACDR) 
 
During my second PhD’s year, I spent six months at the University of Leiden, Ledein 
Academic Centre for Drug Research (LACDR), under the supervision of Professor Ad 
IJzerman, where I carried out a project based on the synthesis of intracellular 
antagonists for CC chemokine receptors CCR1 and CCR2. 
 
INTRODUCTION 
 
Chemokines are small (8-12kDa), inducible, secreted chemotactic cytokines that have 
an highly variability in terms of homology sequence, indeed it is around 20-90%
1,2
. 
They played a critical role in inflammation and immune-surveillance, as they are 
involved in the migration of white blood cells
1
. Furthermore, they are associated to 
tissue repair process and abnormalities, unsuitable utilization or control can cause 
different diseases, such as inflammatory diseases and cancer
2-3
. They are constituted of 
a N terminus in which there is a chemokine domain, then a portion of 110 amino acids, 
especially wealthy in Threonine and Serine, followed by a transmembrane domain and a 
cytoplasmic tail
2
. The chemokine superfamily can be classified, on the basis of the 
configuration of conserved cysteine residues, into four classes, CXC, CC, CX3C and C 
chemokines. Chemokine actions are mediated by specific cell membrane receptors that 
belong to the superfamily of G-protein-coupled receptors (GPCR). Basing on their 
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ligand preference, these receptors have been distinguished as CC, CXC, CX3C and C 
chemokine receptors
1
.
  
 
GPCRs are the vastest family of cell membrane receptors and different kinds of ligands, 
such as neurotrasmitters, ions, hormones, activate them, indeed they are involved in a 
large number of human diseases and disorders
4
. They contain three different subunits α, 
β and γ, knew also as heterotrimeric G proteins αβγ, bind guanine nucleotides: GDP 
(Guanosine diphosphate), reversibly bound in inactivated form, while GTP (Guanosine 
triphosphate) in activated state. Specifically, in the inactivated state the subunits α binds 
GDP and the other two subunits forms a βγ dimer; when a ligand binds the receptor, 
GTP substitutes GDP and binds Gα , followed from release of α-GTP and heterodimer 
βγ and at the end physiological response. The process ends with the hydrolilysis of GTP 
to GDP from Gα , that has GTPase activity and with the regeneration of heterotrimeric 
αβγ2 (Figure 1).  
 
Figure 1 
Furthermore GPCRs can be divided in three different families on the base of homology 
of the sequence and function: 
1. Class A, rhodopsin-like; 
2. Class B, secretin, glucagon, calcitonin receptors; 
3. Class C, metabotropic glutamate receptors5.  
In general there are three main G-protein-mediated signaling pathways, Gq/11, Gi/o and 
Gs that have different effectors. For Gi/o and Gs is cyclic-adenosine 
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monophosphate (cAMP), originated from ATP (cytosolic adenosine triphosphate) by 
action of adenylate cyclase (AC). Gs stimulates adenylate cyclase and increases cAMP, 
while in the opposite way acts Gi/o, indeed it inhibits AC and decreases cAMP. Instead, 
Gq/11 acts through phospholipase C (PLC) that catalyzes the transformation of PIP2 
(phosphatidylinositol-4,5-biphosphate) into DAG (diacylglycerol) and IP3 (inositol-
1,4,5-trisphosphate). These induce Ca
2+
 release, through activation of protein kinase K 
(PKC), and specific receptor binding on the endoplasmic reticulum, respectively 
(Figure 2). 
 
 
Figure 2 
The CC-chemokine receptor CCR-2 is a G protein-coupled membrane receptor, class A, 
expressed on monocytes, dendritic cells and activated T lymphocytes and basophils. It 
consists of about 350 amino-acids with an extracellular N-terminal, necessary for ligand 
binding and specificity, seven helical transmembrane domains with intracellular and 
extracellular loops, and an intracellular C-terminal involved in the signal transduction
6
 
(Figure 3).  
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Figure 3  
This receptor recognizes different ligands such as CCL2 (knew also as monocyte 
chemotactic protein-1, MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), CCL11, CCL13 
(MCP-4), CCL16 (HCC-4). Following interaction with their specific chemokine 
ligands, chemokine receptors trigger a flux in intracellular calcium (Ca
+2
) ions (calcium 
signaling). This causes cell responses, including the onset of a process known as 
chemotaxis, that is the immune cells’ migration towards increasing concentrations of 
chemokines at sites of inflammation. Over the past decade, much evidence has emerged 
suggesting a pathological role of CCL2 and CCR2 in diseases that are characterized by 
chronic inflammation such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, 
allergic rhinitis, allergic asthma, uveitis and solid tumors
7
 but also in cardiovascular 
diseases, organ transplant rejection and diabetes
8
.  
MCP-1 acts on monocytes, basophils and memory T cells by binding to CCR2 and 
generates a chemotactic gradient that triggers the migration of immune cells to the site 
of inflammation. In several inflammatory conditions is observed excessive monocyte 
recruitment and an overexpression of CCL2/CCR2 pair
9
. It has been pointed that, 
through animal model studies of chronic inflammatory diseases, inhibition of binding 
between MCP-1 and CCR-2 by an antagonist suppresses the inflammatory response. 
Furthermore, MCP-1 antagonists inhibit monocyte migration, blocking the development 
of asthma, uveitis and arthritis. MCP-1 has also been found in the nasal mucosa of most 
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patients with dust mite allergies and it induces histamine release from basophils, in 
vitro. Histamines and allergens trigger the expression of MCP-1 and other chemokines 
in the nasal mucosa of people with allergic rhinitis, suggesting the presence of a positive 
feedback loop in such patients
7. So it’s evident that chemokines and their receptors are 
key targets to find a cure for different kinds of disease. In the literature there are various 
inhibitors of CCR2 and especially we have focused our attention on two different 
classes of chemicals, pyrrolidinone as 1
10,11
 and N-benzylindole-2-carboxylic acid as 
2
12
. 
 
 
 
 
 
 
The class of pyrrolidinone 1 is an interesting group of acidic CCR2 antagonists with 
values of IC50 in nanomolar range, so for these compounds, an important SAR study 
was made to better understand the moieties involved in the binding with the receptor. 
Indeed the first investigations were focused on the decoration of C-5 and of amidic 
nitrogen: their removals showed a total decrease of activity. Changing the C-5 aryl 
group with a cyclohexyl group, a great result was obtained with better value of IC50 than 
their lead compound. Was also tried the conversion of the acetyl group with a bigger 
substituent (t-butyl) obtaining worse result in terms of activity. Furthermore, a 
modification of enolic moiety with a methyl group generates a totally inactive 
compounds
10
. Dasse et al. in a further study, describe a new really active pyrrolidinone 
3 obtained from the pyrrolidinone-based CCR2 antagonist 1
11
. 
86 
 
 
They developed a new interesting class of pyrrolidinones through modifications of this 
lead compound 3, identifying the key pharmacophoric moieties of this scaffold, that are 
an hydrophobic alkyl portion, an aromatic group and an ionizable acidic feature. 
Structure-activity relationship study with the aim to investigate this new lead compound 
showed that attempt of methylation or conversion to carboxamide of the hydroxylic 
group, afford new compounds with removal or lowered affinity (respectively IC50 >25 
µM and 2.5 µM). A 30-fold loss of binding affinity was registered with the conversion 
of the acetyl group to ester, while the conversion to amides allow to obtain analogs with 
IC50 values around 1.4-2.0 µM. Instead the removal of acetyl group underlines the 
importance of 1,3-dicarbonyl feature to interact with CCR2, indeed attempts of these 
modifications led to inactive compounds. Really interesting are the introduction of 
halogens such as chlorine, fluorine or bromine on the phenyl group at place of methyl or 
in different positions of the same ring, but keeping in all these cases a substituent in four 
position. Furthermore, it was possible to explore the influence of the cyclohexyl 
functionality to CCR2 binding, substituting it with smaller or larger rings or with allyl 
chains, obtaining only in some case interesting molecules in terms of IC50
11
.  
An important aspect of these compounds is their pharmacokinetics parameters, indeed 
in vivo they show good oral availability and lessened metabolic clearance
11
. They are 
especially indicated for treating of different pathological conditions characterized from 
involvement of  MCP-1, CCR2 or both, such as asthma, food allergy, allergic rhinitis, 
multiple sclerosis, atherosclerosis, cardiac diseases, pulmonary fibrosis, cancer, 
autoimmune diseases, etc...
 13
. Another interesting aspect is that pyrrolidinone type 4 
acts with an allosteric or noncompetitive CCR2 antagonism with respect to CCL2, 
through interaction with an intracellular binding pocket
14-15
. 
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This aspect is really significant in terms of pharmacological properties because 
allosteric modulation displays several advantages from orthosteric one. After interaction 
of allosteric modulators with GPCRs at different sites from the orthosteric one, a 
conformational change in the receptor occurs and this can modify the orthosteric 
ligand’s association/dissociation rate or both in its binding site. Allosteric modulators 
show their effect only in presence of endogenous ligand, modulating his activity in a 
positive or negative mode, furthermore another advantage is that allosteric site’s 
sequence is poorly conserved and in this leads to a higher selectivity
4
.   
Relative to N-benzylindole-2-carboxylic acids of type 2 different patents describe indole 
compounds with N-benzyl moiety as leukotriene biosynthesis’s inhibitors, others as 
allosteric modulators at muscarinic receptors, or antiallergy or for head injury but also 
as MCP-1 inhibitors
16
. In this case through SAR studies, was possible understand the 
principal moiety responsible of this effect. The benzyl group is essential for activity, 
indeed modification with aliphatic group or the total removal, led to total inactive 
molecules. Instead small, lypophilic substituents are well tolerated and also 3,4-
disubstitution led to compounds with higher binding affinity.  Indeed, in further studies 
investigating the role of carboxylic acid the 3,4-dichlorobenzyl analogue 5a has been 
selected as lead compound. 
 
 
 
 
88 
 
The modification of carboxylic acid with tetrazole or acylsulfonamides or amide doesn’t 
lead to better compounds. Finally, substitutions on the indole ring show that strong 
electron withdrawing are generally poorly tolerated save in 3- and 5-positions. Electron 
donating substituents don’t show big differences from the lead compound 5a in terms of 
affinity, instead halogens, expecially fluorine display interesting results with IC50 of 56 
nM. Furthermore, representative N-benzylindole-2-carboxylic acids are tested on 40 
seven-transmembrane G-protein coupled receptor binding assays and all show an IC50 
higher than 10 µM
12
.    
At light of these interesting data, the aim of my project was to prepare the most active 
compounds belong to the pyrrolidinone’s and N-benzylindole-2-carboxylic acid’s 
classes (5-6)
16,17
 and also to synthesize new compounds bearing a proper decoration to 
evaluate their activity against CCR2, but also against CCR1 as high sequence similarity 
of these receptors. The compounds synthesized are indicated below (Table 1): 
 
Compound   R R1 R2 
5a COOH H H 
5b H COOH H 
5c COOH COOH H 
6a 4-bromophenyl Cyclohexyl - 
6b 4-chloro-2-fluorophenyl Cyclohexyl - 
6c 4-chloro-3-methylphenyl Cyclohexyl - 
6d 2-fluoro-4-methylphenyl Cyclohexyl - 
6e 4-chlorophenyl Cyclohexyl - 
6f 3,4-dimethylphenyl 3-pentyl - 
6g 4-methylphenyl 3-pentyl - 
Table 1 
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RESULTS AND DISCUSSION: CHEMISTRY 
Through one-pot reaction was possible to obtain the desired pyrrolidinones 6a-g from 
low to good yields (8-53%). Indeed ethyl-2,4-dioxovalerate 7 was put to react with 
appropriate aldehydes (8a-b) and anilines (9a-g) in acetic acid at 95°C for 2 hours
17
 and 
later through easy filtration or purification by silica gel column cromatography was 
possible to isolate the desired compounds 6a-g (Scheme 1). 
 
Scheme 1 
It was also tried the synthesis of new pyrrolydinones 6h-j starting from the synthesis of 
their appropriate aldehydes 12, 17, 20.  
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To obtain 2-propylpentanal 12 the first attempt was to synthesize 2-propyl-1,2-
epoxypentane 11 by reacting 4-heptanone 10 with sodium hydride and 
trimethylsulfoxonium iodide in DMSO under inert atmosphere at 70°C for 5 hours
18
. 
The epoxide 11, obtained in good yields (40%), was reacted with boron trifluoride 
etherate using benzene
18
 or toluene as solvents (Scheme 2), but unfortunately in both 
cases this reaction didn’t work.  
 
 
Scheme 2  
We tried another synthetic route starting from 2-propyl pentanoic acid 13 that was 
reduced to the corresponding alcohol 14 (76% yield) with dimethyl sulphide borane 
complex in THF at room temperature for 4 hours
19
 and directly oxidized to desired 
aldehyde 12 in high yields (90%), by using Dess-Martin Periodinane reagent in DCM at 
room temperature in 2 hours (Scheme 3). 
 
 
Scheme 3 
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Thus, it was tried the final step with 3,4-dimethylaniline 9f and ethyl-2,4-dioxovalerate 
7 to obtain the corresponding pyrrolidinone 6h but without success. Even changing 
different conditions such as solvents, temperatures, and times of reaction
17
 (Table 2), 
unfortunately we couldn’t isolate the desired product (Scheme 4). 
 
Scheme 4   
Solvent Temperature Time of reaction Result 
Acetic acid glacial 95°C 2 h Side products 
Acetic acid glacial 95°C 3h 30min Side products 
Acetic acid glacial 105°C 2h 30min Side products 
THF room temperature 24h Side products 
Table 2 
 
To synthesize aldehydes 17 and 20 we started from the oxidation, respectively of  4-
hydroxymethyl-piperidine, N-Boc 15 and t-butyl-3-(hydroxymethyl)azetidine-1-
carboxylate 18 by using Dess-Martin Periodinane reagent  as oxidative agent in DCM at 
room temperature 1-2 hours to obtain corresponding aldehydes N-Boc 16 and 19 in high 
yields (83-92%). The protective group N-Boc was removed for reaction with 
trifluoroacetic acid (TFA) in DCM at room temperature
20
 or TFA in a mixture of 
DCM/Water at 0°C
21
.
 
In both cases the reaction was complete in 1 hour (Scheme 5). 
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Scheme 5 
Also in both cases were tried the final step in glacial acetic acid with ethyl-2,4-
dioxovalerate 7 and 3,4-dimethylaniline 9f but we didn’t isolate the desired products 
(Scheme 6). We also tried to carry out the reaction by using the intermediate products, 
16 and 19 respectively, but unfortunately the result was the same.   
Scheme 6 
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We through to change the protective group, quaternizing amines in an easy way with 
methyl iodide, potassium bicarbonate in methanol at 20°C for 24 hours. This method is 
mild and selective and doesn’t attack hydroxyl group22. Furthermore by literature 
research these salts are common used during oxidation reactions. These properties are 
really important in our case. 
The idea was to oxidize the quaternary salts 22a-b with Dess-Martin Periodinane 
reagent in DCM, after that trying to obtain pyrrolidinones 6k-l and finally trough 
cleveage with sodium thiophenolate and 2-butanone at reflux
23
 to isolate the final 
compounds 6i-j (Scheme 7). We decided to start with the six members ring, 4-
(hydroxymethyl)-piperidine, N-Boc 15, that trough the acid catalyzed removal of the 
protective group t-Boc, using TFA and water in DCM at 0°C
21
,
 
gave us amine 21a in 
65% of yield. Unfortunately, the next attempt of quaternization didn’t work and for this 
reason this route was stopped and it wasn’t tried for the corresponding four member 
ring 18. 
 
 
Scheme 7  
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To synthesize N-benzylindole-carboxylic acid 5a-c were planned different routes. 1-
(3,4-Dichlorobenzyl)-1H-indole-2-carboxylic acid 5a was obtained starting from 
phenylhydrazine 24 that was reacted with ethylpyruvate in acetic acid and ethanol at 
reflux for 3 hours to give in good yields (79%) the intermediate  product 25. This one 
by Fischer reaction with polyphosphoric acid at 100°C overnight
24
 gave the indole 26 
(82%), that was reacted with sodium hydride and 3,4-dichlorobenzylchoride in DMF, 
giving the intermediate 27 that was  used as crude for the final step. 
The first attempt of saponification was made by using a 12% KOH solution at reflux for 
3 hours but it wasn’t enough to obtain the carboxylic acid. We tried with lithium 
hydroxide in ethanol at 70°C for 3 hours and then at room temperature overnight. This 
time we isolated the desired 1-(3,4-dichlorobenzyl)-1H-indole-2-carboxylic acid 5a
12,16
 
(Scheme 8).  
 
 
Scheme 8 
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In order to isolate 1-(3,4-dichlorobenzyl)-1H-indole-3-carboxylic acid 5b
25
 was planned 
a first synthetic route starting from indole 28. This compound, in presence of 
trichloroacetyl chloride and pyridine in 1,4-dioxane at reflux for 1 hour and 20 
minutes
26
, was converted in the intermediate compound 29 and than to the 
corresponding ester 30, in quantitative yields, by using potassium t-butoxide as base and 
methanol as solvent. Different methods were tried to obtain compound 31, indeed the 
same method used for other derivate 27 (NaH in DMF with 3,4-dichlorobenzylchloride) 
didn’t work. We tried to change the 3,4-dichlorobenzylchloride with more reactive 3,4-
dichlorobenzylbromide in the same conditions but also in this case the reaction didn’t 
work. Finally we obtained the compound 31, working in two steps. In the first one, the 
starting material 30 was reacted with potassium hydroxide in ethanol and after the 
removal of solvent under reduced pressure, the residue was dissolved in acetone and 
reacted with the 3,4-dichlorobenzylbromide
27
. The crude intermediate compound 31 
was taken up onto the final step of saponification that unfortunately didn’t work, also 
using longer time than the derivate 5a (Scheme 9). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 9 
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Therefore, we decided to continue the synthesis of indole 5b through another synthetic 
route that, at the end, was faster and luckier than the first one.  
We started from the reaction of indole-3-carboxaldehyde 32 with sodium hydride and 
3,4-dichlorobenzylbromide in DMF at 90°C for 3 hours and half
25
. We obtained a good 
final result, isolating compound 33 in high yields (74%).  
Later the oxidation reaction was made using sulfamic acid and sodium chlorite in a 
mixture of acetone and DMSO at 0°C for half hour and then at room temperature 
overnight. In this way, it was possible to obtain the final desired compound 5b in good 
yields (42%) (Scheme 10). 
 
Scheme 10 
Another synthetic route was undertaken to isolate 1-(3,4-dichlorobenzyl)-1H-indole-
2,3-dicarboxylic acid 5c
12,16
.  
A first attempt consisted in a Vilsmeier-Haack reaction to insert an aldehyde function 
on the previous intermediate 27 (scheme 8), using phosphoryl chloride and DMF but 
with low results.  
Therefore, we decided to start from another common intermediate 26 and try again 
Vilsmeier-Haack reaction
28
, obtaining in this case the desired result in high yields 
(78%).  
The further attack of 3,4-dichlorobenzylbromide to NH of indole 34, was conducted 
using the same method described early. Intermediate compound 35 was later oxidised to 
the corresponding carboxylic acid 36 with sulfamic acid and sodium chlorite in a 
mixture of acetone and DMSO at 0°C for half hour and then at room temperature 
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overnight. The final saponification of compound 36 using lithium hydroxide in ethanol 
at 70°C lead to the desired 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dicarboxylic acid 
5c
12,16
 (51%) (Scheme 11). 
 
Scheme 11  
Finally we through to synthesize also the 4F-(3,4-dichlorobenzyl)-1H-indole-2-
carboxylic acid 5d
12,16
 planning a similar route used for previous 1-(3,4-
dichlorobenzyl)-1H-indole-2-carboxylic acid 5a (scheme 8), starting from 3-
Fluorophenylhydrazine hydrochloride 37 (Scheme12).  
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Scheme 12 
Unfortunately in this case the presence of fluorine was a problem for the Fischer 
reaction (Scheme 13), in fact we obtained a mixture of the two possible isomers of 
indole 5d of difficult separation.  
 
 
Scheme 13 
We decided to try another synthetic route changing the steps to isolate the ethyl 4-
fluoroindole-2-carboxylate 39a.  
The first try was made starting from 2-fluorobenzaldehyde 41, dissolved in a 
commercial 25% solution of ethyl azidoacetate in ethanol, that in presence of sodium 
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ethoxide in absolute ethanol would bring to isolate the corrisponding azidoacrylic ester 
42 that directly as crude would be dissolved in cyclohexane and subjected to microwave 
heating to give the desired indole 39a (Scheme 14).  
 
 
Scheme 14 
Unfortunately, these reactions didn’t work and we throught to create directly in situ 
sodium ethoxide dissolving sodium in absolute ethanol, and adding at -10°C the 
solution of 2-fluorobenzaldehyde 41 in ethyl azidoacetate. The resulting yellow 
suspension was stirred  at -10°C for 1 hour and half and for another 1 hour and half at 
0°C
29, but also this attempt didn’t work.  
In the last attempt we changed the times of reaction, indeed we kept the stirring 
suspension at -10°C for two hours and overnight at 0°C, but unfortunately the result was 
the same also this time. 
Other attempts to obtain indole 5d will be tried since the really interesting activity 
against CCR2 from literature research. 
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RESULTS AND DISCUSSION: BIOLOGY 
All compounds synthesized belong to the N-benzylindole-2-carboxylic acid’s and 
pyrrolidinone’s classes (5-6) were submitted to evaluate their activity against CCR2, 
and also against CCR1 as high sequence similarity of these receptors. CCR1 was 
involved in different biological processes such as leukocyte trafficking, gene 
transcription, apoptosis and also the binding of chemokines CCL3, CCL5 and CCL7 to 
CCR1 plays an important role in inflammatory diseases as multiple sclerosis or 
rheumatoid arthritis for the monocytes’, macrophages’ and TH1 cells’ trafficking. 
Indeed antagonism of the binding CCR1-its chemokines could blocks chemotaxis of 
these immune cells
30
.  
The biological screening were assessed in the biological laboratories of Professor 
IJzerman and are indicated in table 3. [
3
H]-CCR2-RA-[R] binding assays were 
performed as reported in the methods section.   
It was very interesting to note as compounds higly active against CCR2 receptor were 
also active against CCR1 receptor. This is a really interesting as these molecules were 
tested, for the first time, also against CCR1 receptor. These molecules seem dual 
antagonists and some with very good affinity actually, as 6a-e and 5a,c. 
All the molecules showed interesting value of affinity with the two receptors at the 
tested concentrations. Regarding pyrrolidinone scaffold we understood that 
modifications in R2 weren’t really important in terms of  selectivity, in opposite to other 
ones in R1 and R3. Furthermore the presence of cyclohexyl group confirms its 
importance for the binding to the receptors CCR2 and CCR1, while the attempt of its 
substitution with an open chain, decreases the affinity values. In addition the presence 
of halogens on the aromatic ring (bromine, fluorine, chlorine) increases the binding 
affinity, indeed compounds 6a-e are the most active compounds of all. Compound 6b, 
bearing fluorine and chlorine on the aromatic ring, shows the best results against both 
receptors, reaching value of 15 nM and 10 nM of Ki against CCR1 and CCR2 
respectively.  
Regarding benzyl-indoles 5a-c was interesting to investigate how different positions of 
the carboxylic group on the indole ring can influence their activity. Indeed, compounds 
with carboxylic group in position 2 (5a,c) were resulted better than other one with 
COOH in position 3 (5b), but there isn’t a clear trend of selectivity. 
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Cmp 
 
 
Scaffold 
 
 
R1 
 
 
R2 
 
 
R3 
CCR1 
 
pKi ± SEM (Ki, nM) 
CCR2 
 
pKi ± SEM (Ki, nM) 
6a  
 
 
 
 
 
 
 
c-hexyl 4-Br Ph -Me 7,6 ± 0,0 (24) 7,8 ± 0,1 (17) 
6b c-hexyl 2-F, 4-Cl Ph -Me 7,8 ± 0,1 (15) 8,0 ± 0,1 (10) 
6c c-hexyl 3-Me, 4-Cl Ph -Me 7,5 ± 0,0 (31) 8,1 ± 0,2 (8) 
6d c-hexyl 2-F, 4-Me Ph -Me 7,6 ± 0,1 (29) 7,5 ± 0,1 (34) 
6e c-hexyl 4-Cl Ph -Me 7,4 ± 0,1 (40) 7,8 ± 0,1 (18) 
6f 3-pentyl 3,4-diMe Ph -Me 6,9 ± 0,1 (117) 7,0 ± 0,1 (108) 
6g 3-pentyl 4-Me Ph -Me 6,9 ± 0,1 (120) 6,8 ± 0,0 (164) 
5a 
 
 
 
 
   7,2 ± 0,1 (66) 7,7 ± 0,0 (18) 
5b 
 
 
 
 
   7,42%a 23,47%a 
5c 
 
 
 
 
 
   7,1 ± 0,0 (74) 7,5 ± 0,1 (36) 
Values are means ± SEM. of at least three independent experiments performed in duplicate.  
a % of displacement at 1 µM, representing the mean of two independent experiments 
Table 3 
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In conclusion most of our compounds showed good affinity against the two receptors  
tested but they aren’t very selective against CCR1 and CCR2. It was possible that dual 
antagonists might be better than just one for diseases in which both receptors are 
involved, using only one drug than two. 
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EXPERIMENTAL SECTION 
CHEMISTRY 
General Methods 
1
H and 
13
C NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (
1
H 
NMR, 400 MHz; 
13
C NMR 100 MHz). All melting points were taken on a Büchi-Tottoli 
apparatus and are uncorrected. Analytical purity of the final compounds was determined 
by high-performance liquid chromatography (HPLC) with a Phenomenex Gemini 3 lm 
C18 110A column (50 x 4.6 mm, 3 m), measuring UV absorbance at 254 nm. All 
compounds showed a single peak at the designated retention time and are at least 95% 
pure. IR spectra were determined with a Shimadzu FT-IR/ATR spectrophotometer. 
Microwave reactions were carried out in a Biotage Emrys™ Optimizer using sealed 
tubes and at a set reaction temperature. Liquid chromatography–mass spectrometry 
(LC–MS) analyses were performed using Thermo Finnigan Surveyor—LCQ Advantage 
Max LC–MS system and a Gemini C18 Phenomenex column (50 x 4.6 mm, 3 m). 
Purification by column chromatography was achieved by use of Grace Davison Davisil 
silica column material (LC60A, 30–200 lm).  
  
Pyrrolidinones’ series   
Synthesis of pyrrolidinones (6a-e)
17
: 
 
 
 
To a stirring solution of appropriate substituted aniline 9a-g (4.42 mmol) in acetic acid 
(4.2 mL) at room temperature were added cyclohexane carboxaldehyde 8a (4.42 mmol) 
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and ethyl-2,4-dioxovalerate 7 (4.42 mmol). The reaction mixture was heated to 95°C for 
2 hours. Upon cooling to room temperature it was concentrated and diethyl ether (10.5 
mL) was added. The resulting mixture was stirred for half an hour, whereupon a 
precipitate forms that was collected by filtration.  
4-Acetyl-1-(4-bromophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 
(6a):  
This compound  was obtained from reaction of 4-bromoaniline 9a with cyclohexane 
carboxaldehyde 8a and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours at 95°C. 
Yield: 53%, white solid; mp: 228-230°C; FT-IR/ATR: 3178, 2926, 2850, 1674, 1651, 
1492, 1446, 1406, 1392, 1217, 1197 cm
-1
; 
1
H NMR (400 MHz, DMSO- d6) δ: 7.63 (d, J 
= 8.7 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 5.07 (d, J = 1.6 Hz, 1H), 2.44 (s, 3H), 1.83 (t, J 
= 10.8 Hz, 1H), 1.59 (d, J = 12.0 Hz, 1H), 1.52-1.34  (m, 4H), 1.03-0.77 (m, 4H), 0.53 
(q, J = 12.4 Hz, 1H); 
13
C NMR (100 MHz, DMSO-d6) δ: 195.81 (s), 164.87 (s), 147.40 
(s), 137.21 (s), 133.01 (s), 132.26 (d x 2), 126.68 (d x 2), 119.03 (s), 61.86 (q), 40.71 
(d), 30.95 (t), 30.03 (t), 27.04 (t), 26.84 (t), 26.45 (t); MS: 380.00; HPLC purity: 98,7% 
; tR: 10.18 min. 
4-Acetyl-1-(4-chloro-2-fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-
pyrrol-2-one (6b):  
This compound was obtained from reaction of 4-chloro-2-fluoroaniline 9b with 
cyclohexane carboxaldehyde 8a and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours 
at 95°C. Yield: 12%, light yellow solid; mp: 195-198°C; FT-IR/ATR: 3151, 2929, 
1689, 1643, 1501, 1220 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 9.10 (bs, 1H), 7.39 (t, J = 
8.2 Hz, 1H), 7.28-7.27 (m, 1H), 7.25 (s, 1H), 4.98 (d, J = 1.7 Hz, 1H), 2.55 (s, 3H), 1.97 
(td, J = 12.4, 2.1 Hz, 1H), 1.71 (d, J = 13.4 Hz,1H), 1.60-1.47 (m, 4H), 1.17-0.85 (m, 
4H), 0.65 (qd, J = 12.4, 3.0 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ: 194.35 (s), 165.03 
(s), 156.24 (d, JC-F = 253.0 Hz), 153.07 (s), 134.38 (d, JC-F = 9.0 Hz), 128.87 (d), 125.31 
(d), 123.51 (s), 120.15 (s), 117.85 (d, JC-F =23.0 Hz), 64.04 (d), 40.76 (q), 30.24 (t), 
30.13 (d), 26.86 (t), 26.50 (t), 26.35 (t), 26.30 (t); MS: 352.13 ; HPLC purity: 95,0% ; tR: 
10.02 min 
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4-Acetyl-1-(4-chloro-3-methylphenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-
pyrrol-2-one (6c):  
This compound was obtained from reaction of  4-chloro-3-methylaniline 9c with 
cyclohexane carboxaldehyde 8a and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours 
at 95°C. Yield: 33%, white solid; mp: 217-218°C; FT-IR/ATR: 3076, 2931, 2852, 1687, 
1643, 1483, 1415, 1276, 1224, 1199 cm
-1
;
 1
H NMR (400 MHz, CDCl3) δ: 7.42 (d, J = 
8.4 Hz, 1H), 7.35 (d, J = 2.4 Hz, 1H), 7.19 (dd, J = 8.4, 2.4 Hz, 1H), 4.96 (d, J = 2.0 Hz, 
1H), 2.57 (s, 3H), 2.44 (s, 3H), 1.95 (td, J = 12.6, 2.0 Hz, 1H), 1.70 (d, J = 12.6 Hz, 
1H), 1.62-1.48 (m, 3H), 1.44 (d, J = 12.6 Hz, 1H), 1.14-0.87 (m, 4H), 0.68 (qd, J = 
12.6, 3.6 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ: 194.20 (s), 176.53 (s), 153.27 (s), 
137.45 (s), 135.31 (s), 132.78 (s), 129.91 (d), 126.52 (d), 122.83 (d), 119.50 (s), 63.44 
(q), 40.70 (q), 30.32 (t), 29.95 (d), 27.48 (t), 26.75 (t), 26.49 (t), 26.29 (t), 20.53 (d); 
MS: 348.07; HPLC purity: 99,2% ; tR: 10.45 min. 
4-Acetyl-5-cyclohexyl-1-(2-fluoro-4-methylphenyl)-3-hydroxy-1,5-dihydro-2H-
pyrrol-2-one (6d):  
This compound was obtained from reaction of 4-fluoro-3-methylaniline 9d with 
cyclohexane carboxaldehyde 8a and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours 
at 95°C. Yield: 35%, white solid; mp: 204-207°C; FT-IR/ATR: 3190, 2926, 2851, 1681, 
1651, 1519, 1402, 1305, 1220 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 7.25 (t, J = 8.3 Hz, 
1H ), 7.04-6.99 (m, 2H), 4.93 (d, J = 1.6 Hz, 1H), 2.55 (s, 3H), 2.42 (s, 3H), 1.97 (td, J 
= 12.5, 2.0 Hz,1H), 1.70 (d, J = 12.5 Hz, 1H), 1.58-1.45 (m, 4H), 1.16-0.86 (m, 4H), 
0.65 (qd, J = 12.5, 3.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ: 194.42 (s), 165.19 (s), 
156.98 (d, JC-F =250.0 Hz), 153.47 (s), 140.31 (s), 127.85 (d), 125.53 (d), 121.94 (s), 
120.09 (s), 117.55 (d, JC-F =19.0 Hz) , 64.17 (q), 40.59 (q), 30.34 (d), 30.05 (t), 26.91 (t), 
26.50 (t), 26.43 (t), 26.35 (t), 21.36 (d); MS: 332.07; HPLC purity: 95,5% ; tR: 9.75 min. 
4-Acetyl-1-(4-chlorophenyl)-5-cyclohexyl--3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 
(6e):  
This compound  was obtained from reaction of  4-chloroaniline 9e with cyclohexane 
carboxaldehyde 8a and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours at 95°C. 
Yield: 48%, yellow solid; mp: 229-231°C; FT-IR/ATR: 3070, 2983, 2926, 1708, 1645, 
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1458, 1394, 1236, 1163, 1139, 1122 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 8.70 (bs, 1H), 
7.41 (d, J = 4.3Hz, 4H), 4.95 (d, J = 2.5 Hz, 1H), 2.53 (s, 3H), 1.93 (td, J = 12.3, 2.7 
Hz, 1H), 1.68 (d, J = 12.3 Hz, 1H), 1.60-1.52 (m, 3H), 1.42 (d, J = 12.3 Hz, 1H), 1.15-
0.84 (m, 4H), 0.66 (qd, J = 12.3, 3.5 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ: 194.07 
(s), 164.89 (s), 143.7 (s), 135.42 (s), 132.36 (s), 129.54 (d x 2), 125.21 (d x 2), 119.03 
(s), 63.11 (d), 40.67 (d), 30.06 (q), 29.93 (t), 27.38 (t), 26.65 (t), 26.38 (t), 26.17 (t); 
MS: 334.00; HPLC purity: 97,9% ; tR: 10.03 min. 
 
Synthesis of Pyrrolidinones (6f-g)
17
: 
 
To a stirring solution of appropriate substituted aniline 9f-g (5.77 mmol) in acetic acid 
(4.2 mL) at room temperature were added 2-ethylbutyraldehyde 8b (5.77 mmol) and 
ethyl-2,4-dioxovalerate 7 (5.77 mmol). The reaction mixture was heated to 95°C for 2 
hours. Upon cooling to room temparature it was concentrated and diethyl ether (10.5 
mL) was added. The resulting mixture was stirred for half an hour, whereupon a 
precipitate forms that was collected by filtration. In absence of precipitate, diethyl ether 
was removed under reduced pressure and the crude was dissolved in few ml of water 
and extracted with ethyl acetate (3 x 10 mL), dried over anhydrous MgSO4, filtered and 
evaporated. It was purified by silica gel column cromatography (DCM:Ethyl Acetate, 
7:3) to give the desired product. 
4-Acetyl-1-(3,4-dimethylphenyl)-3-hydroxy-5-(pentan-3-yl)-1,5-dihydro-2H-pyrrol-
2-one (6f):  
This compound was obtained from reaction of 3,4-dimethylaniline 9f with 2-
ethylbutyraldehyde 8b and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours at 95°C. 
Yield: 9%, white solid; mp: 198-200°C; FT-IR/ATR: 3097, 2960, 2903, 1685, 1647, 
1506, 1456, 1417, 1394, 1284, 1219 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 9.23 (bs, 1H), 
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7.20 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 2.0 Hz, 1H), 7.10 (dd, J = 8.0, 2.0 Hz, 1H) 5.13 (d, 
J = 1.2 Hz, 1H), 2.55 (s, 3H), 2.31 (s, 3H), 2.30 (s, 3H), 1.70 (quint, J = 6.8 Hz, 1H), 
1.37-1.26 (m, 1H), 1.23-1.12 (m, 1H), 1.08-0.98 (m, 1H), 0.93-0.89 (m, 4H), 0.84 (t, J = 
6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ: 194.33 (s), 166.17 (s), 153.07 (s), 137.72 
(s), 135.99 (s), 134.12 (s), 130.33 (d), 125.76 (d), 122.02 (d), 120.19 (s), 60.38 (q), 
43.74 (q), 30.47 (q), 23.18 (t), 21.52 (t), 20.02 (d), 19.53 (d), 12.90 (q), 12.28 (q); MS: 
316.00; HPLC purity: 99,8% ; tR: 10.06 min. 
4-Acetyl-3-hydroxy-1-(4-methylphenyl)-5-(pentan-3-yl)-1,5-dihydro-2H-pyrrol-2-
one (6g): 
This compound was obtained from reaction of p-toluidine 9g with 2-ethylbutyraldehyde 
8b and ethyl-2,4-dioxovalerate 7 in acetic acid in 2 hours at 95°C. Yield: 39%, yellow 
solid; mp: 138-139°C; FT-IR/ATR: 3103, 2962, 2931, 1683, 1647, 1517, 1454, 1400, 
1276, 1220, 1193 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 9.53 (bs, 1H), 7.30-7.25 ( m, 
4H), 5.14 (d,  J = 1.6 Hz, 1H), 2.56 (s, 3H), 2.40 (s, 3H), 1.70 (quint, J = 6.8 Hz, 1H), 
1.36-1.25 (m, 1H), 1.22-1.11 (m, 1H), 1.06-0.97 (m, 1H), 0.93-0.89 (m, 4H), 0.83 (t, J = 
6.8 Hz, 3H);
 13
C NMR (100 MHz, CDCl3) δ: 194.36 (s), 165.39 (s), 152.85 (s), 137.26 
(s), 133.87 (s), 129.90 (d x 2), 124.56 (d x 2), 120.46 (s), 60.46 (q), 43.74 (q), 30.60 (d), 
23.21 (t), 21.52 (t), 21.19 (d), 12.89 (q), 12.31 (q); MS: 302.03; HPLC purity: 99,9% ; 
tR: 9.69 min. 
 
Synthesis of 2-propyl-1,2-epoxypentane (11)
18
:  
 
To a stirring mixture of sodium hydride (0.33 g, 14 mmol) and trimethylsulfoxonium 
iodide (2.9 g, 13.12 mmol) under N2 atmosphere DMSO (10.6 mL) was slowly added. 
Hydrogen evolution caused and when the gas evolution was complete, 4-heptanone 10 
(1 g, 8.75 mmol) was added and the reaction mixture was heated at 70°C for 5 hours. 
After cooling to room temperature, the mixture reaction was poured into water (15 mL) 
and extracted with ethyl acetate (3 x 15 mL). The organic layer was washed with water 
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(20 mL) and brine (20 mL), dried over anhydrous MgSO4, filtered and evaporated to 
give the desired compound 12. The epoxide was used for the next step without further 
purification that unfortunately didn’t work. Yield: 40%. The spectroscopic data are in 
agreement with the literature
18
.  
 
Synthesis of 2-propylpentan-1-ol (14):  
 
To a solution of 2-propyl-pentanoic acid 13 (1 g, 6.93 mmol) in THF (8.15 mL) at 0°C 
was added slowly borane dimethyl sulfide complex (2.8 mL, 2.77 mmol). The reaction 
mixture was stirred with gradual warming to room temperature for 4 hours, recooled to 
0°C and quenched with MeOH (8-10 mL). It was concentrated under reduced pressure 
and the resulting crude was diluted with water (10 mL) and extracted with ethyl acetate 
(3 x 10 mL). The organic extract was washed with brine, dried over anhydrous MgSO4, 
filtered and evaporated in vacuo to give the desired compound 14, which was used 
without further purification. Yield: 76%, colorless oil.
 1
H NMR (400 MHz, CDCl3) δ: 
0.85 (t, J = 7.2 Hz, 6H), 1.18-1.31 (m, 8H), 1.42-1.44 (m, 1H), 3.09 (s, 1H), 3.43 (d, J = 
5.6 Hz, 2H). 
 
Synthesis of 2-propylpentanal (12): 
 
2-Propylpentan-1-ol 14 (0.3 g, 2.3 mmol) was dissolved in DCM (15 mL) and under N2 
atmosphere was added Dess-Martin Periodinane reagent (1.4 g, 3.22 mmol) and the 
reaction mixture was stirred at room temperature for 2 hours. The solution was diluted 
with water (25 mL) and extracted with diethyl ether (3 x 15 mL). The organic layer was 
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washed with an aqueous 5% Na2S2O3 solution (30 mL) and an aqueous saturated 
NaHCO3 solution (30 mL), dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to give desired aldehyde 12. Yield: 90%, white solid. The spectroscopic data are 
in agreement with the literature
18
.  
 
Synthesis of 1-t-butoxycarbonyl-4-formylpiperidine (16): 
 
4-(Hydroxymethyl)-piperidine, N-Boc 15 (0.2 g, 0.93 mmol) was dissolved in DCM (5 
mL) and under N2 atmosphere was added Dess-Martin Periodinane reagent (0.55 g, 1.30 
mmol) and the reaction mixture was stirred at room temperature for 1 hour. The solution 
was diluted with water (20 mL) and extracted with diethyl ether (3 x 5 mL). The organic 
layer was washed with an aqueous 5% Na2S2O3 solution (20 mL) and an aqueous 
saturated NaHCO3 solution (20 mL), dried over anhydrous MgSO4, filtered and 
evaporated. It was purified by silica gel column cromatography (DCM:Ethyl Acetate, 
8:2) to give the desired product 16. Yield: 92%, colorless oil. The spectroscopic data are 
in agreement with the literature
31
.  
 
Synthesis of 4-formylpiperidine (17): 
 
To a solution of 1-t-butoxycarbonyl-4-formylpiperidine 16 (0.5 g, 2.34 mmol) in DCM 
(2 mL) was added TFA (1.65 g, 14.51 mmol), and the resulting solution was stirred at 
room temperature for 2 hours. Concentration of the solution and the concentrate was 
poured into an aqueous saturated NaHCO3 solution (10 mL) and extracted with ethyl 
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acetate (3 x 10 mL). The organic layer was dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. The crude was taken up onto the final step that unfortunately 
didn’t work. 
 
Synthesis of tert-butyl 3-formylazetidine-1-carboxylate (19): 
 
t-Butyl-3-(hydroxymethyl)azetidine-1-carboxylate 18 (1.0 g, 5.34 mmol) was dissolved 
in DCM (25 mL) and under N2 atmosphere was added  Dess-Martin Periodinane reagent 
(3.2 g, 7.48 mmol) and the reaction mixture was stirred at room temperature for 3 hours. 
The solution was diluted with water (40 mL) and extracted with diethyl ether (3 x 25 
mL). The organic layer was washed with an aqueous 5% Na2S2O3 solution (50 mL) and 
an aqueous saturated NaHCO3 solution (50 mL), dried over anhydrous MgSO4, filtered 
and concentrated under reduced pressure. The crude product was purified by silica gel 
column cromatography (DCM:Ethyl Acetate, 75:25) to give the desired aldehyde 19. 
Yield: 83%, colorless oil. The spectroscopic data are in agreement with the literature
32
.  
 
Synthesis of azetidine-3-carbaldehyde  (20):   
 
To a solution of t-butyl-3-formylazetidine-1-carboxylate 19 (0.32 g, 1.75 mmol) in 
DCM (7.3 mL) were added TFA (7.3 mL) and water (0.75 mL) and the resulting 
solution wa stirred at 0°C for 1 hour. After concentration  the crude was dissolved in a 
mixture of MeOH:H2O (1:3, 29.21 mL) and neutralized with 2M NaOH solution. The 
reaction mixture was stirred at 0°C for 12 hours. The most of solvent was removed 
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under reduced pressure and the concentrate was extracted with ethyl acetate (3 x 20 
mL). The crude was taken up onto the final step that unfortunately didn’t work.  
 
Synthesis of (piperidin-4yl)methanol (21a): 
 
To a solution of 4-(hydroxymethyl)-piperidine, N-Boc 15 (0.3 g, 1.39 mmol) in DCM 
(5.8 mL) were added TFA (5.8 mL) and water (0.6 mL) and the resulting solution was 
stirred at 0°C for 1 hour. After concentration the crude was dissolved in a mixture of 
MeOH:H2O (1:3, 23.2 mL) and neutralized with 2M NaOH solution. The reaction 
mixture was stirred at 0°C for 12 hours. The most of solvent was removed under 
reduced pressure and the concentrate was extracted with ethyl acetate (3 x 15 mL). 
Yield: 65%, light yellow oil. The spectroscopic data are in agreement with the 
literature
33
.  
 
Indoles’ series  
Synthesis of ethyl 2-(2-phenylhydrazinylidene)propanoate (25): 
 
 
A mixture of phenylhydrazine 24 (1.0 g, 9.2 mmol), ethyl pyruvate (1.74 g, 15 mmol), 
and glacial acetic acid (0.10 mL) in anyhydrous ethanol (9.92 mL) was heated to reflux 
for 3 hours. Upon cooling to room temperature, the most of solvent was removed under 
reduced pressure, and the concentrate was extracted with ethyl acetate (3 x 10 mL), 
dried over anhydrous MgSO4, filtered and evaporated to give the crude product. It was 
purified by silica gel column cromatography (DCM) to afford the desired product 25. 
Yield: 79%, yellow solid; 
1
H NMR (400 MHz, CDCl3) δ: 7.67 (s, 1H), 7.31 (t, J = 7.2 
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Hz, 2H), 7.21 (d, J = 1.2 Hz, 2H), 6.97 (t, J = 7.2 Hz, 2H), 4.32 (q, J = 7.2 Hz, 2H), 
2.11 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H).
 
The data are in agreement with the literature. 
Other spectroscopic data (mp, IR, 
13
C-NMR) are reported as well
34
. 
 
Synthesis of ethyl 1H-indole-2-carboxylate (26): 
 
 
A mixture of ethyl 2-(2-phenylhydrazinylidene)propanoate 25
 
(0.8 g, 3.87 mmol) and 
polysphoric acid (9.3 g, 95.03 mmol) was heated to 100°C overnight, then it was poured 
into crush ice with acutely stirring, extracted with ethyl acetate (3 x 15 mL), dried over 
anhydrous MgSO4, filtered and concentrated to give the crude product, that was used 
directly for the next step without purification. Yield: 82%, brown solid; 
1
H NMR (400 
MHz, DMSO- d6) δ: 11.87 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 
7.25 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 1.6, 1H), 7.07 (t, J = 7.6 Hz, 1H), 4.33 (q, J = 7.2 
Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H);
 13
C NMR (100 MHz, DMSO-d6) δ: 161.39 (s), 137.52 
(s), 127.41 (s), 126.8 (s), 124.68 (d), 122.10 (d), 120.18 (d), 112.70 (d), 107.73 (d), 
60.52 (t), 14.33 (q). The data are in agreement with the literature. Other spectroscopic 
data (mp, IR) are reported as well
28,35
.
 
 
 
 
Synthesis of 1-(3,4-dichlorobenzyl)-1H-indole-2-carboxylic acid (5a): 
 
 
 
To a solution of ethyl 1H-indole-2-carboxylate 26 (0.35 g, 1.85 mmol) in dry DMF (4 
mL), sodium hydride  (0.053 g, 2.22 mmol) was added at 0°C and the reaction mixture 
was stirred for 1 hour and half at room temperature. 3,4-dichlorobenzyl chloride (0.54 g, 
113 
 
2.27 mmol) was added and the reaction mixture was stirred at room temperature for 1 
hour and half. Then the reaction was poured into ice and brine (10 mL) and the aqueous 
solution was extracted with ethyl acetate (3 x 10 mL), dried over anhydrous MgSO4, 
filtered and concentrated under reduced pressure. The crude was taken up onto the next 
step. 
To a suspension of crude (0.2 g, 0.5 mmol) in ethanol (5 mL) was added lithium 
hydroxide (0.07 g, 2.85 mmol) and the reaction mixture was heated to 70°C for 3 hours, 
and then at room temperature overnight. It was poured into ice water and acidified with 
1M HCl. A light yellow precipitate was filtered off. Yield on two step: 40%, light 
yellow solid; mp: 189-190°C; FT-IR/ATR: 2983, 2870, 1708, 1645, 1506, 1458, 1394, 
1238, 1122 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 7.75 (d, J = 8.0 Hz, 1H), 7.56 (s, 1H), 
7.36 (d, J = 7.6 Hz, 1H), 7.31 (t, J = 8.0 Hz, 2H) 7.21 (t, J = 7.6 Hz, 1H), 7.17 (s, 1H), 
6.86 (d, J = 8.4 Hz, 1H), 5.78 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ: 166.06 (s), 
139.94 (s), 138.35 (s), 132.84 (s), 131.43 (s), 130.70 (d), 128.39 (d), 126.48 (d), 126.17 
(s), 126.03 (s), 125.76 (d), 123.29 (d), 121.50 (d),  113.83 (d), 110.60 (d), 47.03 (t); MS: 
no signal in ms, but previous reaction (ethylester) showed correct ms; HPLC purity: 
98,2%; tR: 10.28 min. The spectoscopic data are in agreement with the literature
12,16
. 
 
 
Synthesis of 2,2,2-trichloro-1-(1H-indol-3-yl)ethanone (29)
26
:  
 
 
 
A solution of indole 28 (1.0 g, 8.53 mmol) in dry dioxane (3,5 mL) was dropped into a 
mixture of trichloro-acetyl chloride (1.86 g, 10.22 mmol), pyridine (0.84 mL), and dry 
1,4-dioxane (13.4 mL). After 80 minutes the reaction mixture was poured into 50 mL of 
water and the precipitate filtered, washed with water and pentane to give the desired 
product 29. Yield: 80%, light brown solid; mp: 231-234°C (decomp.); FT-IR/ATR: 
3248, 3201, 1639, 1510, 1429, 1236, 1153 cm
-1
; 
1
H-NMR (400 MHz, DMSO-d6) δ: 
12.55 (s, 1H), 8.60 (d, J = 3.4 Hz, 1H), 8.20 (sest, J = 3.2 Hz, 1H), 7.59 (sest, J = 2.8 
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Hz, 1H), 7.32 (sest, J = 3.2 Hz, 2H); 
13
C NMR (100 MHz, DMSO-d6 ): 177.23 (s), 
137.18 (d), 136.62 (d), 127.57 (s), 124.29 (d), 123.62 (d), 121.73 (d), 113.42 (d), 105.22 
(s), 66.86 (s). The spectoscopic data are in agreement with the literature
26
. 
 
Synthesis of methyl 1H-indole-3-carboxylate (30):  
 
 
 
To a solution of potassium t-butoxide (0.042 g, 0.38 mmol) and methanol (5 mL) was 
added 2,2,2-trichloro-1-(1H-indol-3-yl)ethanone 29 (0.1 g, 0.38 mmol) and the reaction 
mixture was stirred at room temperature for 1 hour. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography (DCM) to 
afford the corresponding product 30. Yield: 100%, white solid; mp: 146-148°C 
(decomp.); FT-IR/ATR: 3232, 3199, 1662, 1525, 1442, 1195 cm
-1
; 
1
H NMR (400 MHz, 
CDCl3) δ: 8.81 (s, 1H), 8.24-8-22 (m, 1H), 7.94 (d, J = 2.8 Hz, 1H), 7.42-7.39 (m, 1H), 
7.28-7.25 (m, 2H), 3.93 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ: 165.9, 136.1, 131.2, 
125.7, 123.2, 121.4, 111.6, 108.6, 51.1. The data are in agreement with the literature. 
Other spectroscopic data (mp, 
13
C NMR) are reported as well
36
.  
 
Synthesis of methyl 1-(3,4-dichlorobenzyl)-1H-indole-3-carboxylate (31): 
 
 
 
Potassium hydroxide (0.062 g, 0.89 mmol) was added at room temperature to a solution 
of methyl 1H-indole-3-carboxylate 30 (0.16 g, 0.89 mmol) in ethanol (7.42 mL). After 
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stirring until total solubilization, the ethanol was totally removed under reduced 
pressure and acetone (7.42 mL) was added followed by 3,4-dichlorobenzylbromide 
(0.21 g, 0.89 mmol). Immediately a precipitate was formed that was filtered and the 
filtrate concentrated to give the crude of desired product. The crude was taken up onto 
the final step of saponification that unfortunately didn’t work. 
 
Synthesis of 1-(3,4-dichlorobenzyl)-indole-3-carboxaldehyde (33): 
 
 
The indole-3-carboxaldehyde 32 (1.0 g, 6.89 mmol) was dissolved in dry DMF (8.3 
mL) and the stirred solution was treated with sodium hydride (0.2 g, 8.27 mmol). The 
reaction mixture was stirred at room temperature for 15 minutes. 3,4-Dichlorobenzyl 
bromide (2.0 g, 8.27 mmol) was added and the reaction mixture was maintained at 90 
ºC for 3 hours and half. Upon cooling the crude was poured onto ice and acidified with 
2N-HCl, whereupon a precipitate forms ant it was collected by filtration. Yield: 74%, 
white solid; 
1
H NMR (400 MHz, CDCl3) δ: 10.03 (s, 1H), 8.35-8.30 (m, 1H), 7.74 (s, 
1H), 7.42 (d, J = 8.3 Hz, 1H), 7.36-7.32 (m, 2H), 7.29-7.26 (m, 2H), 6.98 (dd, J = 8.3, 
2.2 Hz, 1H), 5.33 (s, 2H) ppm; 
13
C NMR (100 MHz, CDCl3) δ: 184.68 (d), 138.19 (d), 
137.22 (s), 135.72 (s), 133.45 (s), 132.72 (s), 131.21 (d), 129.01 (d), 126.30 (d), 125.57 
(s), 124.54 (d), 123.38 (d), 122.40 (d), 118.95 (s), 110.19 (d), 49.89 (t) ppm. The data 
are in agreement with the literature. Other spectroscopic data (mp and IR) are reported 
as well
37
. 
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Synthesis of 1-(3,4-dichlorobenzyl)-1H-indole-3-carboxilic acid (5b): 
 
 
 
To a solution of 1-(3,4-dichlorobenzyl)-indole-3-carboxaldehyde 33 (0.6 g, 1.97 mmol)  
in a mixture of DMSO (8.6 mL) and acetone (21.3 mL) was added an aqueous solution 
(6.5 mL) of sulfamic acid (0.33 g, 3.37 mmol). The solution was cooled at 0ºC and an 
aqueous solution (14.7 mL) of sodium chlorite (0.36 g, 3.94 mmol) was slowly added. 
The reaction was stirred at 0ºC for 30 minutes and then at room temperature overnight. 
Water (40.5 mL) was added and the precipitate was filtered off. It was purified by silica 
gel column chromatography (DCM). Yield: 42%, white solid; mp: 210-213°C; IR 
(Perkin-Elmer 298 Nujol): 1650, 1525, 1275, 1190 cm
-1
;
 1
H NMR (400 MHz, DMSO- 
d6) δ: 12.09 (bs,1H), 8.29 (s, 1H), 8.03 (dd, J = 6.6, 3.2 Hz, 1H), 7.63 (d, J = 1.7 Hz, 
1H), 7.60 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 6.8, 3.2 Hz, 1H), 7.24-7.20 (m, 3H), 5.52 (s, 
2H); 
13
C NMR (100 MHz, DMSO-d6) δ:166.05 (s), 138.92 (s), 136.64 (s), 136.05 (d), 
131.74 (s), 131.45 (d), 130.85 (s), 129.92 (d), 128.15 (d), 127.12 (s), 123.08 (d), 122.09 
(d), 121.48 (d), 111.53 (d), 107.75 (s), 48.74 (t); MS: 319.87; HPLC purity: 99,9%; tR: 
9.60 min. The data are in agreement with the literature. Other spectroscopic data (mp 
and IR) are reported as well
25
. 
 
Synthesis of ethyl-3-formyl-1H-indole-2-carboxylate (34)
28
: 
 
 
 
Phosphorus oxychloride (POCl3) (0.44 g, 2.9 mmol) was added dropwise to dry DMF (1 
mL) at 0ºC, after 5 minutes a solution of ethyl-1H-indole-2-carboxylate 26 (0.5 g, 2.64 
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mmol) in dry DMF (3 mL) was added and the resulting mixture was stirred at room 
temperature for 1 hour and at 70ºC for 6 hours. The reaction mixture was poured into 
cold water and neutralized with 2M NaOH. The yellow precipitate was collected by 
filtration to give the desired product. Yield: 78%, light brown powder; 
1
H NMR (400 
MHz, DMSO- d6) δ: 12.84 (s, 1H), 10.63 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.41 (dt, J = 
7.2, 1.2 Hz, 1H), 7.31 (dt, J = 7.2, 1.2 Hz, 1H), 4.47 (q, J = 7.2 Hz, 2H), 1.41 (t, J = 7.2 
Hz, 3H). The data are in agreement with the literature. Other spectroscopic data (mp, 
IR, 
13
C-NMR) are reported as well
28,38
. 
 
Synthesis of  ethyl-1-(3,4-dichlorobenzyl)-3-formyl-1H-indole-2-carboxylate (35):  
 
 
 
A solution of ethyl-3-formyl-1H-indole-2-carboxylate 34 (0.2 g, 0.92 mmol) in dry 
DMF (3 mL) was added dropwise under N2 atmosphere to an ice-cooled suspension of 
sodium hydride (0.033 g, 1.38 mmol) in dry DMF (2 mL). After stirring at 0 ºC for 20 
minutes, 3,4-dichlorobenzylbromide (0.26 g, 1.10 mmol) was added dropwise and the 
reaction mixture was warmed to room temperature and stirred overnight. It was poured 
into ice-water (10 mL) and then extracted with ethyl acetate (3 x 15 mL), dried over 
anhydrous MgSO4, filtered and evaporated in vacuo. It was purified by silica gel 
column cromatography (Petroleum Ether:DCM, 8:2) to give the desired product 35. 
Yield: 80%, yellow oil; FT-IR/ATR: 2983, 2870, 1708, 1645, 1458, 1394, 1236, 1139, 
1122 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 10.37 (s, 1H), 7.19-7.02 (m, 7H), 5,49 (s, 
2H), 4.20 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ: 
188.54 (d), 160.84 (s), 138.16 (s), 137.09 (s), 133.07 (s), 132.86 (s), 131.89 (s), 130.85 
(d), 128.40 (d), 126.91 (d), 125.70 (d), 124.72 (s), 124.55 (d), 124.15 (d), 120.69 (s), 
110.54 (d), 62.48 (t), 47.70 (t), 14.24 (q). 
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Synthesis of 1-(3,4-dichlorobenzyl)-2-(ethoxycarbonyl)-1H-indole-3-carboxylic acid 
(36): 
 
 
 
 
To a solution of ethyl 1-(3,4-dichlorobenzyl)-3-formyl-1H-indole-2-carboxylate 35 
(0.26 g, 0.69 mmol) in a mixture of DMSO (3 mL) and acetone (7.5 mL) was added an 
aqueous solution (2.5 mL) of sulfamic acid (0.11 g, 1.18 mmol). The solution was 
cooled at 0ºC and an aqueous solution (5 mL) of sodium chlorite (0.12 g, 1.38 mmol) 
was added slowly. The reaction was stirred at 0ºC for 30 minutes and then at room 
temperature overnight. Water (14.2 mL) was added and extracted with ethyl acetate (3 x 
15 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo. It was purified 
by silica gel column cromatography (DCM:Ethyl Acetate, 95:5) to give the desired 
product 36. Yield: 78%, light orange solid; mp: 165-166°C; FT-IR/ATR: 2922, 2850, 
1716, 1660, 1541, 1435, 1398, 1236, 1192 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ: 8.38 
(dd, J = 6.8, 2.0 Hz, 1H), 7.41-7.35 (m, 3H), 7.33-7.29 (m, 1H), 7.14 (d, J = 2.0 Hz, 
1H), 6.90 (dd, J = 8.0, 2.0 Hz, 1H), 5.5 (s, 2H), 4.42 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 7.2 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ: 166.21 (s), 163.49 (s), 144.52 (s), 137.11 (s), 
136.80 (s), 136.59 (s), 133.22 (s), 132.16 (s), 130.98 (d), 128.32 (d), 126.62 (s), 126.35 
(d), 125.56 (d), 123.93 (d), 123.75 (d), 110.44 (d), 63.41 (t), 48.26 (t), 13.83 (q). 
 
Synthesis of 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dicarboxylic acid (5c):  
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To a solution of 1-(3,4-dichlorobenzyl)-2-(ethoxycarbonyl)-1H-indole-3-carboxylic acid 
36 (0.21 g, 0.54 mmol) in ethanol (5 mL) at room temperature was added lithium 
hydroxide (0.070 g, 2.85 mmol) and the mixture reaction was heated at 70ºC for 2 hours 
and then at room temperature overnight. It was poured into ice water (10 mL) and 
acidified with 2M HCl. A yellow precipitate was filtered off. Yield: 51%, yellow 
powder; mp: 252-255°C; FT-IR/ATR: 2983, 2870, 1708, 1645, 1458, 1394, 1236, 1139, 
1122 cm
-1
; 
1
H NMR (400 MHz, DMSO- d6) δ: 8.50 (d, J = 7.8 Hz, 1H), 7.50 (q, J = 8.3 
Hz, 2H), 7.38 (d, J = 1.9 Hz, 1H), 7.26 (dt, J = 7.0, 1.2 Hz, 1H), 7.18 (t, J = 7.0 Hz, 
1H), 6.99 (dd, J = 8.4, 2.0 Hz, 1H), 6.11 (s, 2H); 
13
C NMR (100 MHz, DMSO-d6) δ: 
166.42 (s), 163.69 (s), 146.08 (s), 139.12 (s), 136.42 (s), 136.29 (s), 131.63 (s), 131.32 
(d), 130.49 (s), 129.24 (d), 127.43 (d), 126.05 (s), 125.01 (d), 123.07 (d), 122.80 (d), 
111.87 (d), 47.19 (t); MS: 363.80; HPLC purity: 97,5%; tR: 9.83 min. The spectoscopic 
data are in agreement with the literature
12,16
. 
 
BIOLOGY 
 
Chemicals and Reagents 
CCR2-RA-[R] was synthesized in-house in agreement with  the literature
10
. [
3
H]-CCR2-
RA-[R] (specific activity 59,6 Ci mmol
−1
) was custom-labeled by Vitrax (Placentia, 
CA), for which a dehydrogenated precursor was provided ((R)-4-acetyl-1-(4-chloro-2-
fluorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one). Bovine serum 
albumin (BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). 
Bicinchoninic acid (BCA) and BCA protein assay reagent were purchased from Pierce 
Chemical Company (Rockford, IL, USA). Tango™ CCR1-bla and CCR2-bla U2OS 
cells stably expressing the human CCR1 or human CCR2 (U2OS-CCR1 or U2OS-
CCR2) were obtained from Invitrogen (Carlsbad, CA). All other chemicals were 
obtained from standard commercial sources. 
Cell culture  
Human osteosarcoma (U2OS) cells stably expressing the human CCR1 or CCR2 
(Invitrogen, Carlsbad, CA) were cultured in McCoy’s 5A medium supplemented with 
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10% (v/v) fetal calf serum, 2 mM glutamine, 0,1 mM nonessential amino acids 
(NEAAs), 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM 
sodium pyruvate, 100 IU/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml G418, 50 
μg/ml hygromycin, and 125 μg/ml zeocin (200 μg/ml zeocin for U2OS-CCR1) in a 
humidified atmosphere at 37°C and 5% CO2. Cells were subcultered twice weekly at a 
ratio of 1:4 to 1:6 on 10-cm Ø and 15-cm Ø plates by trypsinization.  
Cell membrane preparation  
Membranes were prepared as described in the literature
14
. Briefly, cells were detached 
from 15-cm Ø plates by scraping into 5 ml of phosphate-buffered saline (PBS) and 
subsequently centrifuged for 5 minutes at 3000 rpm (200 x g). The pellets were 
resuspended in ice-cold 50 mM Tris-HCl buffer and 5 mM MgCl2, pH 7.4, and 
homogenized with an Ultra Turrax homogenizer (IKA-Werke GmbH & Co. KG, 
Staufen, Germany). Membranes and the cytosolic fraction were separated by several 
centrifugation steps at 31,000 rpm in an Optima LE-80 K ultracentrifuge (Beckman 
Coulter, Inc., Fullerton, CA) at 4°C for 20 minutes. Finally, the membrane pellet was 
resuspended in 50 mM Tris-HCl buffer and 5 mM MgCl2, pH 7.4, and aliquots of 100 
μl and 250 μl were stored at -80°C. Membrane protein concentrations were measured 
using a BCA protein determination with BSA as a standard
39
. 
[
3
H]-CCR2-RA-[R] binding assays  
[
3
H]-CCR2-RA-[R] binding assays were performed in a 100 μL reaction volume 
containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% CHAPS and 5 to 15 
μg of membrane protein at 25 ºC. Displacement assays with U2OS-CCR1 or –CCR2 
were carried out with an average concentration of 6.0 nM [
3
H]-CCR2-RA-[R]. In all 
cases, at least six concentrations of competing ligand were incubated for 120 min at 25 
ºC. Non-specific binding was determined in the presence of 10 μM CCR2-RA-[R]. In 
all cases, total radioligand binding did not exceed 10% of the amount added to prevent 
ligand depletion. For all experiments incubations were terminated by dilution with ice-
cold 50 mM Tris-HCl buffer supplemented with 0.05% CHAPS. Separation of bound 
from free radioligand was performed by rapid filtration through a 96-well GF/B filter 
plate using a Perkin Elmer Filtermate harvester (Perkin Elmer, Groningen, the 
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Netherlands). Filters were washed 10 times with ice-cold wash buffer. 25 μL of 
Microscint scintillation cocktail (Perkin-Elmer, Groningen, the Netherlands) was added 
to each well and the filter-bound radioactivity was determined by scintillation 
spectrometry using the P-E 2450 Microbeta
14
 scintillation plate-counter (Perkin Elmer, 
Groningen, The Netherlands).  
Data analysis  
All experiments were analyzed using the non-linear regression curve fitting program 
Prism 6 (GraphPad, San Diego, CA, U.S.A.). The IC50 values of CCR2-RA-[R] were 
obtained by non-linear regression analysis of the displacement curves. The IC50 values 
of the unlabeled ligands obtained from radioligand displacement experiments were 
converted into Ki values using the Cheng-Prusoff equation
40
. All values obtained are 
means of at least three independent experiments performed in triplicate, unless stated 
otherwise. 
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